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Complement receptor (Cr)1 and Cr2 have long been studied in relation to humoral 
immunity. These receptors are alternative splice variants of the murine Cr2 gene, and all 
previous investigations of the effect of Cr1 and Cr2 on humoral immunity have been 
conducted utilizing mouse models deficient in both Cr1 and Cr2. To date, very little 
effort has been taken to delineate the functional roles of each receptor. The known 
molecular differences and independent transcription of Cr1 and Cr2 suggest a functional 
significance for each of these that should not be ignored. Additionally, I discovered that 
Cr1 and Cr2 are differentially expressed by follicular dendritic cells (FDCs) and B cells. 
It is shown here that B cells predominantly express Cr2, while Cr1 is the near exclusive 
Cr2 product on FDCs. To investigate the independent roles of Cr1 and Cr2 in the context 
of an immune response, I generated two new mouse strains: Cr1KO and Cr2KO. The 
predominance of Cr1 on FDCs led to the hypothesis that Cr1 primarily functions in FDC 
promotion of germinal center (GC) reactions, which is likely mediated by the known 
complement-dependent deposition of immune complexes in follicles. Analysis of these 
new strains demonstrated that Cr1 and Cr2 have marked differences in their function in 
humoral immunity. In many cases, the B cell responses which are decreased in the Cr1/2-
deficient mouse are unaffected in the Cr1-deficient mouse. It is shown that Cr1-




and memory B cell production. Intriguingly, classically GC-independent responses, such 
as antigen-specific IgM and IgM memory B cells, are also reduced. However, B cell 
responses that cannot proceed through germinal centers, notably T-independent B cell 
responses, are not affected by Cr1-deficiency. In total, this work defines the Cr1KO and 
Cr2KO mouse lines as new models for the study of Cr1 and Cr2 in humoral immunity. In 
addition to its use in the study of the function of Cr1, the Cr1KO mouse is an invaluable 
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Activation of the complement system has long been accepted to bridge the rapid 
response of the innate immune system to the high specificity of the adaptive immune 
response (1). Complement activation results in the generation of complement component 
3 (C3) products that covalently bond with microorganisms or antigen, effectively 
marking them as foreign. These tags, known as opsonins, facilitate recognition and 
phagocytosis by various complement receptors on immune cells. Binding of opsonized 
proteins in this manner leads to immune effects through complement receptor signaling, 
display for detection by other receptors, and phagocytic uptake. Utilization and regulation 
of this system is co-opted by B cells and follicular dendritic cells (FDCs) using 
complement receptors (Cr) 1 and 2 to enhance humoral immunity (2). Despite extensive 
work in vitro and the use of various Cr2 null mice to determine the in vivo effects of 
Cr1/2, little is known about the independent roles of Cr1 and Cr2. It is also unknown why 
the shorter Cr2 form is generated from an alternative splice. Cr1, which is encoded by 
inclusion of all the exons of Cr2, contains all the binding domains that Cr2 also exhibits. 
To investigate the importance of these receptors independently, we generated two new 
mouse lines. In the first mutant strain, all the Cr1-specific exons were deleted. In the 
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second mutant strain, the alternatively spliced exons were fused to remove the alternative 
splice site required for Cr2. 
 
The Complement Cascade 
  The complement cascade has many members, effectors, and three modes of 
initiation. The cascade can be generally simplified into three steps: initiation via foreign 
molecule recognition, activation of C3, and targeted destruction by membrane attack 
complex formation. In addition to this last textbook outcome of complement cascade 
activation, enhancement of many effector functions such as immune cell recruitment, 
phagocytosis, and humoral immunity occur (3).  
Initiation of the complement cascade is achieved in three distinct manners: the 
classical, mannose-binding lectin, and alternative pathways. The classical pathway is so 
named because it was the first to be discovered. It is initiated when immunoglobulin 
binds cells bringing the complement activation domains of immunoglobulins into close 
proximity where they are able to recruit and form the cascade-activating C1 complex (3). 
The C1 complex consists of the subunits C1qC1rC1s. Together these proteins 
initiate the complement cascade by cleaving C4 into C4b and C4a. C4b then binds with 
C2a (the major not minor portion of C2) and they become a C3 convertase (4, 5). C3 
convertases are enzymatically active complement protein complexes (C3bBb or C4b2a) 
that cleave C3 into C3a and C3b (Figure 1.1). C3a, like the related molecule C5a, is a 
potent activation and recruitment molecule, known as an anaphylatoxin (6). C3b forms a 
covalent thioester bond with cells and antigens at the site of activation and has many 
functions. C3b itself may form a complex with the factor B protein, Bb, forming a new  
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Figure 1.1. Initiation of all three complement pathways results in cleavage of C3 and 
covalent binding of C3b to the activating antigen. Antigen shown in green can be quickly 
detected by the complement pathways, resulting in the activation of the complement 
cascade and the opsonization of antigen by C3b via a thioester bond. Cleavage of the C3 
protein also results in the release of the potent anaphylatoxin into the surrounding 
immune environment. C3b participation in C3 convertases facilitates the generation of 
more C3a and C3b. Regulatory proteins may further cleave C3d, resulting in inactivation 









C3 convertase (5). In this way, C3b formation itself may act to begin a positive feedback 
loop and continuously generate more C3b and C3a. Additionally, C3b may be cleaved by 
regulatory proteins into iC3b and C3d. Reduction to these fragments abolishes their 
ability to take part in a C3 convertase complex but makes them available for various 
receptors: Cr1, Cr2, Cr3, and Cr4. Inclusion of an additional C3b in either C3 convertase 
complex generates a C5 convertase. C5 convertases generate C5a a potent anaphylatoxin, 
as well as the membrane attack complex, which is a pore forming complex made of 
complement proteins C5 through C9. Deposition of the membrane attack complex on cell 
membranes causes lysis of targeted cells.  
The mannose-binding lectin pathway and alternative pathway are similar to the 
classical pathway after the activation of C3. The mannose-binding lectin pathway is 
however initiated by detection of the common bacterial cell component mannose, and the 
alternative pathway is initiated simply by spontaneous deposition and cleavage of C3 on 
cells and molecules that do not express protective regulatory proteins. 
 
Complement Receptors 1 and 2 
 Cr1 and Cr2 (Cr will denote murine complement receptors and CR will denote 
human complement receptors) are capable of binding fragments of C3. Cr1 and Cr2 share 
a large portion of sequence in common due to their production as alternatively spliced 
transcripts from the same Cr2 gene (Figure 1.2) (7). The additional exons included to 
make Cr1 encode the first six short consensus repeat (SCR) domains of the 21 that make 
up Cr1 (8). In humans, these exons have become pseudoexons (8); however, humans 







Figure 1.2. The Cr2 gene encodes two splice variants, Cr1 and Cr2. Splicing of all the 
exons including those shown in blue into the final transcript generates Cr1. The exons in 






include sites with binding specificity for C3b (Figure 1.3) as well as for factor I, which is 
the enzyme that cleaves C3b into iC3b or C3d(g) (10-12). In contrast, Cr2 binds C3d(g) 
and iC3b (Figure 1.3) (12, 13). To some extent, Cr2 binds C3b as well as C3d(g) and 
iC3b, but the affinity for the latter two is tremendously greater (13). Cr1 contains all the 
domains within Cr2 and should bind all the above fragments of C3; however, it has never 
been tested if any subtle secondary structure differences affect the C3d(g) and iC3b 
binding affinity of Cr1.    
 Extensive in vitro studies have elucidated the role of Cr2 as the B cell co-receptor 
(14-17). These studies determined that Cr2 is organized into a signaling complex with 
CD19 and CD81 and that binding of complement-bound immune complexes by Cr2 
enhances the response of B cell receptor stimulation (BCR) (17). Cr2 alone does not 
initiate an intracellular signaling cascade, but instead when bound by C3d(g) or iC3b 
(referred to as just C3d from here on) bound antigen initiates signaling via CD19 (18). 
CD81 and other proteins organize the complex. These members associate and together 
make up the B cell co-receptor (Figure 1.4). Although direct testing of mouse Cr2 
amplification of BCR signaling is less extensive than that shown for human CR2, the 
parallel function of the two is widely accepted. Amplification has been directly shown by 
Chakravarty et al. 2002 (19) and the close homology of CR2 and CD19 between their 
respective murine and primate counterparts suggests a conservation of function (7, 20). 
Additionally, immunoprecipitation of CR2 (human/mouse) or CD19 from transfected 
immortal A20 mouse B cells co-precipitates the entire CR2-CD19-CD81 B cell co-







Figure 1.3. Respective C3b and C3d (as well as C3d(g) and iC3b) binding regions on Cr1 
and Cr2. Cr1 also binds and acts as a cofactor for the protease factor I which converts 












Figure 1.4. Follicle and GC organization. Upon antigen encounter within the B cell 
follicle, B cells migrate to the perifollicular region at the border of the follicle-T cell zone. 
These B cells then expand before migrating back to the region around the FDCs and 
generating a GC. GC B cells then cycle back and forth between periods of proliferation in 
the dark zone and periods of selection among T cells and FDCs in the light zone. GCs 






Cr1 and Cr2 binding differences are at the root of the general overarching 
question of this thesis. In light of the fact that all C3 fragments that bind Cr2 also bind 
Cr1, it is interesting that Cr2 is produced independently of Cr1. The independent nature 
of Cr1 and Cr2 have generally been ignored by all current research. The few exceptions 
include the identification of a generally inflamed splenic microenvironment of Cr1/2KO 
mice (22), identification of an excessive cytokine response by Cr1/2KO mice following 
adenovirus infection (23), and a demonstration that transgenic expression of human CR2 
in Cr1/2KO mice rescues antibody production deficiencies (24). However, these studies 
did not definitively establish the effects of Cr1- or Cr2-deficiency independently. The 
first two studies used Cr1/2KO mice. The third set of studies were performed on three 
independent human CR2 transgenic mice that were generated on a Cr2-/- background 
(note the Cr2-/- is a Cr2-null (25) but not the same as the Cr1/2KO (26)). These model 
mice all had various disadvantages. The first mouse was created by inserting CR2 with its 
endogenous human CR2 promoter and never produced high levels of CR2 (21). The 
second mouse transgenically expressed CR2 under the immunoglobulin lambda chain 
promoter and resulted in premature expression of CR2 during development of B cells. 
This premature expression caused a partial block in B cell development at the pro-B cell 
stage (27, 28). A third mouse was successfully generated in which CR2 was expressed at 
an appropriate stage and in appropriate quantities for mouse and human comparisons (24). 
As intriguing as these mice are for investigations of human CR2, they, like the original 
two, do not allow for the definitive study of Cr1-deficiency because human CR2 is not 
expressed in its autochthonous environment and cannot be assumed to be filling the roles 
of mouse Cr2. Additionally, a CR1 transgenic mouse, in which CR1 is driven by the 
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lamda light chain promoter, was created on the Cr2-/- mouse strain (29). The expression 
of CR1 in this mouse line by the lamda chain promoter drives expression in B cells but 
likely fails to drive expression in FDCs, which is the opposite of Cr1 in mice. Again this 
is an intriguing model for the study of CR1 in mice, but I would argue it is not truly an 
analogous replacement of Cr1. In the absence of previous tools or direct studies, we 
generated the independent Cr1 and Cr2 knockout mice (Cr1KO and Cr2KO) in order to 
assess the effects mediated by complement and these receptors on humoral immunity. 
 
B cells and Humoral Immunity 
 Interest in Cr1 and Cr2 is generated by their selective expression on FDCs and B 
cells. B cells are the cells that are singularly responsible for the production of antibodies. 
Each B cell produces antibody, or immunoglobulin, of one specificity. Through a process 
known as VDJ rearrangement, B cells as a group produce a nearly unlimited number of 
antigen-specific immunoglobulin possibilities (30). The repertoire of specificities is 
limited more by the number of cells in an organism than by the repertoire possibilities. B 
cells that respond to antigen can in some cases undergo a process known as somatic 
hypermutation (SHM), a process by which mutations are directed to the coding sequences 
of the immunoglobulin binding regions (31). Targeted SHM is dependent on the 
mutation-generating enzyme activation-induced cytidine deaminase (AID). SHM 
provides a B cell with new immunoglobulin specificity that may in fact have a higher 
affinity than the original immunoglobulin.  
There are two main categories of B cells: the innate like B1 cells and the B2 cells 
that undergo processes in order to produce highly specific and diverse antibodies. B1 
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cells are an interesting set of B cells that have recently undergone a surge of interest, 
which has expanded our knowledge of their role in immunity. There are two subsets of 
B1 cells: B1a and B1b (32). Functionally, B1a cells produce natural antibody (32) and 
B1b cells are responsible for producing T-independent antigen memory (33, 34). B1a 
cells are also dependent on Cr2-CD19 signaling for their development. Both reduction 
and deletion of Cr2 result in a reduction of the number of B1a cells in mice ((35) and 
Figure 3.3). The Cr1/2KO mouse has been shown to have depressed natural antibody 
titers and this has been used to explain the Cr1/2KO mouse resistance to ischemia 
reperfusion injury (ischemia reperfusion injury is a disease mediated at least in part by 
natural antibody targeting of complement activation to apoptotic tissues (36, 37)). 
However, it has also been suggested that the effect may be due to a non-C3 ligand effect 
such as desensitization due to CD19 overexpression (38). It was these findings that led us 
to ask if Cr1 was required for B1a cell development or whether the off target effects of 
CD19 overexpression alone resulted in B1a loss and natural antibody reduction. The roles 
of Cr1 and Cr2 in B1 cells and natural antibody production are tested and discussed in 
Chapter 3.  
 A subset of B2 cells known as marginal zone (MZ) B cells are found within the 
spleen. As their name suggests, MZ B cells are found in the MZ of the spleen (39). The 
MZ is the compartment within the spleen in which blood from arterioles is first delivered. 
The nature of the MZ is such that cells present there are constantly bathed in any blood-
borne antigen. The location of MZ B cells is consistent with their major function of 
responding with “innate” like quickness to blood borne pathogens. Like B1 cells, MZ B 
cells have a lower and broader immunoglobulin affinity repertoire. Similar to follicular B 
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cells (FO B cells), MZ B cells are capable of undergoing extensive class switch 
recombination (CSR), a process by which immunoglobulin specificity is maintained but 
the effector region is changed (40). In MZ B cells, CSR predominantly targets switching 
to IgG3 and some IgG2a (41, 42). MZ B cells are conventionally understood to respond 
quickly to T-independent antigens, especially repetitive type 2 antigens (TI-2) (39, 43). 
To a limited extent, MZ B cells are capable of taking part in germinal center reactions 
(GCs) and undergoing SHM (44). Typical TI-2 antigens, such as polysaccharides, are 
highly repetitive molecules capable of eliciting massive B cell receptor (BCR) 
crosslinking on single cells. Another important property of TI-2 antigens is that they are 
not peptide based and therefore cannot be presented by major histocompatibility-II 
complexes (MHC-II) to elicit T cell help. A well-documented instance of the importance 
of the response to TI-2 antigen is the MZ B cell response to polysaccharides, such as 
those that make up the capsule of the pathogen Streptococcus pneumoniae (S. 
pneumoniae) (39, 41). The virulence of S. pneumoniae is strongly determined by the 
polysaccharide capsule, of which nearly 100 variants have been described (45). The 
importance of MZ B cells and neutralization of the capsule combined with the late 
formation of the marginal zone in humans (~2 years of age) is likely the reason that 
young children are particularly susceptible to S. pneumoniae infections (39). Cr1/2KO 
mice have been found to exhibit significantly reduced antibody responses to TI-2 
antigens and S. pneumoniae (26). These mice also survive infection with S. pneumoniae 
at considerably lower rates than wildtype (WT) (26, 46). The marked effects of Cr1/2 
deficiency on TI-2 antigens led us to investigate the effect of Cr1-deficiency on these 
responses using the Cr1KO mouse strain (Chapter 3).    
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 FO B cells are highly migratory B cells that conventionally respond to peptide 
based T-dependent (TD; T cell/Thymus-dependent) antigen, take part in germinal center 
reactions, and are the precursors of high affinity and long-term memory effectors. They 
constantly migrate between lymph nodes and the spleen to increase their chances of 
encountering antigen. The progression from a naïve FO B cell to mature long-term 
memory B cell or high affinity antibody-producing plasma cell requires antigen 
recognition, perifollicular expansion of antigen specific B cells, and coordinated 
expansion and selection in GCs. Fate determination as a memory or plasma cell must also 
occur and despite its major importance is still a very poorly understood phenomenon.  
 
Antigen recognition by FO B cells 
Within any given mouse, antigen-specific B cells are found relatively infrequently 
(~1000s-10,000s) (47). In order to raise the chances of FO B cell encounter with antigen, 
the immune system is organized to concentrate antigen in sites where FO B cells are 
present or frequently visiting. In a snapshot of FO B cell localization, one would find B 
cells mostly in peripheral immune tissues. However, FO B cells are in fact highly motile 
and a single mature FO B cell spends only about a day in any given peripheral immune 
organ (48). Exit from the lymph/blood and trafficking to the follicles is guided by 
CXCR5 detection of the chemokine CXCL13. Within the follicles, FO B cells may 
encounter antigen displayed on the surface of subcapsular macrophages, dendritic cells, 
and FDCs (48). Soluble and small particulate antigen may be captured by dendritic cells 
or subcapsular macrophages and trafficked to follicles, or it may diffuse into the follicles 
via conduits (49, 50). Capture, detection, and response to soluble antigens is greatly 
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enhanced by the presence of antibody, while larger particulate antigens are readily 
captured and deposited in follicles in the absence of antibody (51). The role of FDCs and 
Cr as major contributors of antigen display is well established but poorly understood. Use 
of the Cr1KO to ask questions about humoral immunity in the absence of Cr on FDCs is 
addressed in Chapters 3 and 4.  
 
Perifollicular expansion 
 In the current model of a B cell response to TD antigen, FO B cells that have been 
activated by their cognate antigen upregulate the receptors EBI2 and CCR7 and traffic to 
the follicle perimeter at the border with the adjacent T cell zone (52, 53). It is here that a 
large pool of clones of antigen-specific B cells is initially generated in conjunction with 
the help of T cell (Figure 1.4). The expansion of these cells presumably provides 
“individuals” to select from during the initial stages of the GC reactions. These clones 
exhibit limited CSR and no SHM before they are recruited to GCs at about four or five 
days (54).  
 
Germinal centers 
 GCs are conventionally understood to be the organized sites where B cells 
undergo SHM after activation by their cognate antigen. Surprisingly, much of the biology 
of GCs is still poorly understood. A role for GCs that faces little dispute is their 
importance in affinity maturation. Many studies demonstrate some GC-independent 
pathways for CSR, large antibody responses, and memory B cell generation. However,  
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essentially no evidence of affinity maturation in the absence of GCs has been 
demonstrated (55-57). It is within GCs that GC B cells go through cycles of AID-driven 
SHM, clonal expansion, and testing of the newly mutated immunoglobulin (55-57). 
Presumably, this testing occurs against the antigen retained on the FDCs; however, this is 
an open topic of research (58). These GC B cells consist of the FO B cells initially 
generated in the perifollicular region. Within the GC, two zones have long been 
recognized by their visibly two-toned appearance. The light zone (LZ) contains cells that 
have been classically called centrocytes (55). These GC B cells are in close contact with 
FDCs and interact frequently with GC T cells (Figure 1.4). In contrast, the dark zone 
(DZ) is characterized by the presence of B cells, classically termed centroblasts (55). 
These cells are highly proliferative and endow the dark zone with its darker color due to 
their high DNA content. Recently, the GC B cells in the light zone and dark zone were 
demonstrated to be distinguishable by their differential expression of the markers CXCR4, 
CD83, and CD86 (59). In general, the centrocyte and centroblast terms overlap with the 
LZ B cell and DZ B cell marker, cell cycle, and AID phenotypes.  
 
Memory B cells and plasma cells 
Generally, it has been found that much of the long-term memory and long-lived 
plasma cell output is through a GC-dependent pathway, and that most of these cells 
exhibit switched immunoglobulin from IgM to IgG, IgA, or IgE (40). Portions of this 
model, however, are unknown or are found to be heterogeneous in nature. Recent 
evidence suggests that even the long held belief that IgM+ cells are not GC-derived and 
IgG positive cells are GC-derived is generally true only for the latter. Multiple groups 
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have shown a collection of both GC-independent and GC-dependent IgM+ memory B 
cells (60-62). Furthermore, the mechanisms of memory B cell and plasma cell fate 
determination are poorly understood. Three possible mechanisms for fate determination 
have been suggested: inherent B cell receptor signaling differences, environmental 
differences including T cell/FDC input, and a temporal switch that may shift the output of 
the GC (63). Experiments investigating the effect of Cr1-deficiency on GC output are 
discussed in Chapter 4. Additionally, utilization of the Cr1KO mouse as a tool to 
investigate these mechanisms of fate determination is discussed in Chapter 4 as well as in 
the Summary and Conclusion. 
 
Follicular Dendritic Cells 
 FDCs are centrally located in B cell follicles and upon formation of GCs take a 
prominent position in the LZ (64). The current model of FDC function is one in which 
they define the follicle, concentrate antigen on their surface for surveillance, produce 
adhesion molecules that enhance B cell interactions, and secrete cytokines to promote B 
cell survival (Figure 1.4). Recently, the importance of FDCs was demonstrated by 
deletion of FDCs at the initiation of GCs.  This study showed that FDC ablation 
significantly reduced GCs and resulted in disorganization of both the T zone and follicles 
(65). Important FDC genes were reduced or lost from peripheral immune tissue after 
FDC ablation as well. Most notable of these was the B cell recruitment chemokine 
CXCL13. The importance of FDCs has also been demonstrated by the loss of B cell 
organization and GC formation in the absence of the stromal produced B cell survival 
factors lymphotoxin, TNF, or IKK (66, 67).  
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Antigen retention is one of the major functions of FDCs and its complement 
dependence makes it of particular interest here. Early studies discovered that iodinated 
proteins quickly became deposited on cells in follicles and germinal centers (68, 69). 
Later, the antigen was shown to be deposited on FDCs as immune complexes termed at 
the time iccosomes (70, 71). This immune complex trapping in primary immune follicles 
was determined to be dependent on complement and expression of a product of the Cr2 
gene (72). This same study determined that secondary immune follicle trapping of 
immune complexes could occur in an FcγIIRB receptor-dependent manner. More 
recently, it was shown that Fc receptors are not prevalent until immunization causes their 
upregulation (73), highlighting the importance of Cr in the capture of antigen in the 
primary response. The advent of knockout mouse technology and the engineering of mice 
with Cr2 gene mutations led to extensive studies of complement receptors on FDCs just 
as it had for B cells (2, 74). These studies demonstrated the requirement of Cr for 
deposition of antigen on FDCs. Chapter 3 defines the novel finding of the Cr1 
predominance over Cr2 on FDCs. This prompted the hypothesis tested in Chapter 4 that 




 The importance of complement as an endogenous adjuvant has been well known 
for the last 40 years (1). Defining of the Cr1/2 complement-binding domains (11, 13) and 
the unprecedented mapping of CR2’s B cell co-receptor function (15-18) provided a solid 
foundation for the in vivo studies that followed. These in vivo studies began with the 
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generation of multiple Cr2-/- mice (25, 26) and a Cr2 hypomorphic mouse (35) which 
demonstrated the dramatic influence of both B cell- and FDC-expressed Cr on humoral 
immunity. I hypothesized, however, that Cr1 and Cr2 have distinct functions in the 
bridging of complement detection of antigen to humoral immunity. To investigate these 
independent functions, we engineered two new mouse strains specifically deficient in 
either Cr2 or Cr1: the Cr2KO and Cr1KO mice (Chapters 2 and 3/4, respectively). 
Despite the established role of Cr2 as a member of the B cell co-receptor complex and 
multiple studies that attributed B cell response deficiencies to Cr2 co-receptor function, it 
had always been an outstanding question as to why Cr1 could not fill this role by itself. In 
Chapter 2, I describe the generation and characterization of the Cr2KO mouse strain to 
investigate this question. In Chapter 3, I describe the generation of the Cr1KO mouse 
strain and the previously unappreciated differential expression of Cr1 between B cells 
and FDCs. The role of Cr1 is tested in relation to B1, MZ B, and FO B cell populations. 
Previously identified phenotypes in the Cr1/2KO and C3KO mouse strains are utilized to 
compare the requirements of Cr1 and Cr2. Humoral immune deficiencies consistent with 
an FDC-based role for Cr1 are elucidated, which lead to the investigation in Chapter 4 of 
the requirement for FDC-expressed Cr1 in GC B cell dynamics and memory B cell 
generation. In this chapter, I elaborate on the extent of the GC deficiencies found in the 
Cr1KO mouse strain. In total, the work described here characterizes two new mouse 
models that provide strong evidence for the important and independent roles of Cr1 and 
Cr2, with special attention given to Cr1. Analysis of the Cr1KO strain further opens up 
avenues for research involving the differences of early versus late GC B cells, the 
importance of antigen retention on affinity, the role for Cr1 on FDC cellular functions, 
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and the effect of GC B cell numbers on immune outcome. Additionally, these studies 
uncovered obvious parallels between Cr1 and CR2L and suggest that an understanding of 
Cr1 functions may uncover mechanisms for targeted enhancement of immunizations.      
 
References 
1. Pepys, M. B. 1974. Role of complement in induction of antibody production in vivo. 
Effect of cobra factor and other C3-reactive agents on thymus-dependent and 
thymus-independent antibody responses. J. Exp. Med. 140: 126–145. 
 
2. Carroll, M. C., and D. E. Isenman. 2012. Regulation of humoral immunity by 
complement. Immunity 37: 199–207. 
 
3. Walport, M. J. 2001. Complement. First of two parts. N. Engl. J. Med. 344: 1058–
1066. 
 
4. Sjöberg, A. P., L. A. Trouw, and A. M. Blom. 2009. Complement activation and 
inhibition: a delicate balance. Trends Immunol. 30: 83–90. 
 
5. Zipfel, P. F., and C. Skerka. 2009. Complement regulators and inhibitory proteins. 
Nat. Rev. Immunol. 9: 729–740. 
 
6. Guo, R.-F., and P. A. Ward. 2005. Role of C5a in inflammatory responses. Annu. 
Rev. Immunol. 23: 821–852. 
 
7. Kurtz, C. B., M. S. Paul, M. Aegerter, J. J. Weis, and J. Weis. 1989. Murine 
complement receptor gene family. II. Identification and characterization of the 
murine homolog (Cr2) to human CR2 and its molecular linkage to Crry. J. Immunol. 
143: 2058–2067. 
 
8. Holguin, M. H., C. B. Kurtz, C. J. Parker, J. J. Weis, and J. Weis. 1990. Loss of 
human CR1- and murine Crry-like exons in human CR2 transcripts due to CR2 
gene mutations. J. Immunol. 145: 1776–1781. 
 
9. Liu, Y. J., J. Xu, O. de Bouteiller, C. L. Parham, G. Grouard, O. Djossou, B. de 
Saint-Vis, S. Lebecque, J. Banchereau, and K. W. Moore. 1997. Follicular dendritic 
cells specifically express the long CR2/CD21 isoform. J. Exp. Med. 185: 165–170. 
 
10. Kinoshita, T., S. Lavoie, and V. Nussenzweig. 1985. Regulatory proteins for the 
activated third and fourth components of complement (C3b and C4b) in mice. II. 




11. Molina, H., T. Kinoshita, C. B. Webster, and V. M. Holers. 1994. Analysis of 
C3b/C3d binding sites and factor I cofactor regions within mouse complement 
receptors 1 and 2. J. Immunol. 153: 789–795. 
 
12. Kalli, K. R., and D. T. Fearon. 1994. Binding of C3b and C4b by the CR1-like site 
in murine CR1. J. Immunol. 152: 2899–2903. 
 
13. Pramoonjago, P., J. Takeda, Y. U. Kim, K. Inoue, and T. Kinoshita. 1993. Ligand 
specificities of mouse complement receptor types 1 (CR1) and 2 (CR2) purified 
from spleen cells. Int. Immunol. 5: 337–343. 
 
14. Carter, R. H., M. O. Spycher, Y. C. Ng, R. Hoffman, and D. T. Fearon. 1988. 
Synergistic interaction between complement receptor type 2 and membrane IgM on 
B lymphocytes. J. Immunol. 141: 457–463. 
 
15. Matsumoto, A. K., J. Kopicky-Burd, R. H. Carter, D. A. Tuveson, T. F. Tedder, and 
D. T. Fearon. 1991. Intersection of the complement and immune systems: a signal 
transduction complex of the B lymphocyte-containing complement receptor type 2 
and CD19. J. Exp. Med. 173: 55–64. 
 
16. Matsumoto, A. K., D. R. Martin, R. H. Carter, L. B. Klickstein, J. M. Ahearn, and 
D. T. Fearon. 1993. Functional dissection of the CD21/CD19/TAPA-1/Leu-13 
complex of B lymphocytes. J. Exp. Med. 178: 1407–1417. 
 
17. Carter, R. H., and D. T. Fearon. 1992. CD19: lowering the threshold for antigen 
receptor stimulation of B lymphocytes. Science 256: 105–107. 
 
18. Tedder, T. F., M. Inaoki, and S. Sato. 1997. The CD19-CD21 complex regulates 
signal transduction thresholds governing humoral immunity and autoimmunity. 
Immunity 6: 107–118. 
 
19. Chakravarty, L., M. D. Zabel, J. J. Weis, and J. Weis. 2002. Depletion of Lyn 
kinase from the BCR complex and inhibition of B cell activation by excess CD21 
ligation. Int. Immunol. 14: 139–146. 
 
20. Tedder, T. F., and C. M. Isaacs. 1989. Isolation of cDNAs encoding the CD19 
antigen of human and mouse B lymphocytes. A new member of the 
immunoglobulin superfamily. J. Immunol. 143: 712–717. 
 
21. Marchbank, K. J., C. C. Watson, D. F. Ritsema, and V. M. Holers. 2000. 
Expression of human complement receptor 2 (CR2, CD21) in Cr2-/- mice restores 
humoral immune function. J. Immunol. 165: 2354–2361. 
 
22. Jacobson, A. C., J. J. Weis, and J. Weis. 2008. Complement receptors 1 and 2 
influence the immune environment in a B cell receptor-independent manner. J. 
 21 
Immunol. 180: 5057–5066. 
 
23. Seregin, S. S., Y. A. Aldhamen, D. M. Appledorn, N. J. Schuldt, A. J. McBride, M. 
Bujold, S. S. Godbehere, and A. Amalfitano. 2009. CR1/2 is an important 
suppressor of Adenovirus-induced innate immune responses and is required for 
induction of neutralizing antibodies. Gene Ther. 16: 1245–1259. 
 
24. Kulik, L., K. Chen, B. T. Huber, and V. M. Holers. 2011. Human complement 
receptor type 2 (CR2/CD21) transgenic mice provide an in vivo model to study 
immunoregulatory effects of receptor antagonists. Mol. Immunol. 48: 883–894. 
 
25. Molina, H., V. M. Holers, B. Li, Y. Fung, S. Mariathasan, J. Goellner, J. Strauss-
Schoenberger, R. W. Karr, and D. D. Chaplin. 1996. Markedly impaired humoral 
immune response in mice deficient in complement receptors 1 and 2. Proc. Natl. 
Acad. Sci. USA 93: 3357–3361. 
 
26. Haas, K. M., M. Hasegawa, D. A. Steeber, J. C. Poe, M. D. Zabel, C. B. Bock, D. R. 
Karp, D. E. Briles, J. Weis, and T. F. Tedder. 2002. Complement receptors 
CD21/35 link innate and protective immunity during Streptococcus pneumoniae 
infection by regulating IgG3 antibody responses. Immunity 17: 713–723. 
 
27. Marchbank, K. J., L. Kulik, M. G. Gipson, B. P. Morgan, and V. M. Holers. 2002. 
Expression of human complement receptor type 2 (CD21) in mice during early B 
cell development results in a reduction in mature B cells and 
hypogammaglobulinemia. J. Immunol. 169: 3526–3535. 
 
28. Kulik, L., K. J. Marchbank, T. Lyubchenko, K. A. Kuhn, G. A. Liubchenko, C. 
Haluszczak, M. G. Gipson, M. G. Gibson, S. A. Boackle, and V. M. Holers. 2007. 
Intrinsic B cell hypo-responsiveness in mice prematurely expressing human 
CR2/CD21 during B cell development. Eur. J. Immunol. 37: 623–633. 
 
29. Pappworth, I. Y., C. Hayes, J. Dimmick, B. P. Morgan, V. M. Holers, and K. J. 
Marchbank. 2012. Mice expressing human CR1/CD35 have an enhanced humoral 
immune response to T-dependent antigens but fail to correct the effect of premature 
human CR2 expression. Immunobiology 217: 147–157. 
 
30. Teng, G., and F. N. Papavasiliou. 2007. Immunoglobulin somatic hypermutation. 
Annu. Rev. Genet. 41: 107–120. 
 
31. Maizels, N. 2005. Immunoglobulin gene diversification. Annu. Rev. Genet. 39: 23–
46. 
 
32. Baumgarth, N. 2011. The double life of a B-1 cell: self-reactivity selects for 
protective effector functions. Nat. Rev. Immunol. 11: 34–46. 
 
33. Haas, K. M., J. C. Poe, D. A. Steeber, and T. F. Tedder. 2005. B-1a and B-1b cells 
 22 
exhibit distinct developmental requirements and have unique functional roles in 
innate and adaptive immunity to S. pneumoniae. Immunity 23: 7–18. 
 
34. Alugupalli, K. R., J. M. Leong, R. T. Woodland, M. Muramatsu, T. Honjo, and R. 
M. Gerstein. 2004. B1b lymphocytes confer T cell-independent long-lasting 
immunity. Immunity 21: 379–390. 
 
35. Ahearn, J. M., M. B. Fischer, D. Croix, S. Goerg, M. Ma, J. Xia, X. Zhou, R. G. 
Howard, T. L. Rothstein, and M. C. Carroll. 1996. Disruption of the Cr2 locus 
results in a reduction in B-1a cells and in an impaired B cell response to T-
dependent antigen. Immunity 4: 251–262. 
 
36. Williams, J. P., T. T. Pechet, M. R. Weiser, R. Reid, L. Kobzik, F. D. Moore, M. C. 
Carroll, and H. B. Hechtman. 1999. Intestinal reperfusion injury is mediated by IgM 
and complement. J. Appl. Physiol. 86: 938–942. 
 
37. Fleming, S. D., T. Shea-Donohue, J. M. Guthridge, L. Kulik, T. J. Waldschmidt, M. 
G. Gipson, G. C. Tsokos, and V. M. Holers. 2002. Mice deficient in complement 
receptors 1 and 2 lack a tissue injury-inducing subset of the natural antibody 
repertoire. J. Immunol. 169: 2126–2133. 
 
38. Woods, K. M., M. R. Pope, S. M. Hoffman, and S. D. Fleming. 2011. CR2+ 
marginal zone B cell production of pathogenic natural antibodies is C3 independent. 
J. Immunol. 186: 1755–1762. 
 
39. Martin, F., and J. F. Kearney. 2002. Marginal-zone B cells. Nat. Rev. Immunol. 2: 
323–335. 
 
40. Xu, Z., H. Zan, E. J. Pone, T. Mai, and P. Casali. 2012. Immunoglobulin class-
switch DNA recombination: induction, targeting and beyond. Nat. Rev. Immunol. 
12: 517–531. 
 
41. Guinamard, R., M. Okigaki, J. Schlessinger, and J. V. Ravetch. 2000. Absence of 
marginal zone B cells in Pyk-2-deficient mice defines their role in the humoral 
response. Nat. Immunol. 1: 31–36. 
 
42. Zheng, Y., M. Yu, A. Podd, L. Yuan, D. K. Newman, R. Wen, G. Arepally, and D. 
Wang. 2013. Critical role for mouse marginal zone B cells in PF4/heparin antibody 
production. Blood 121: 3484–3492. 
 
43. Martin, F., A. M. Oliver, and J. F. Kearney. 2001. Marginal zone and B1 B cells 
unite in the early response against T-independent blood-borne particulate antigens. 
Immunity 14: 617–629. 
 
44. Phan, T. G., S. Gardam, A. Basten, and R. Brink. 2005. Altered migration, 
recruitment, and somatic hypermutation in the early response of marginal zone B 
 23 
cells to T cell-dependent antigen. J. Immunol. 174: 4567–4578. 
 
45. Yother, J. 2011. Capsules of Streptococcus pneumoniae and other bacteria: 
paradigms for polysaccharide biosynthesis and regulation. Annu. Rev. Microbiol. 
65: 563–581. 
 
46. Haas, K. M., J. C. Poe, and T. F. Tedder. 2009. CD21/35 promotes protective 
immunity to Streptococcus pneumoniae through a complement-independent but 
CD19-dependent pathway that regulates PD-1 expression. J. Immunol. 183: 3661–
3671. 
 
47. Pape, K. A., J. J. Taylor, R. W. Maul, P. J. Gearhart, and M. K. Jenkins. 2011. 
Different B cell populations mediate early and late memory during an endogenous 
immune response. Science 331: 1203–1207. 
 
48. Cyster, J. G. 2010. B cell follicles and antigen encounters of the third kind. Nat. 
Immunol. 11: 989–996. 
 
49. Roozendaal, R., T. R. Mempel, L. A. Pitcher, S. F. Gonzalez, A. Verschoor, R. E. 
Mebius, U. H. von Andrian, and M. C. Carroll. 2009. Conduits mediate transport of 
low-molecular-weight antigen to lymph node follicles. Immunity 30: 264–276. 
 
50. Gonzalez, S. F., S. E. Degn, L. A. Pitcher, M. Woodruff, B. A. Heesters, and M. C. 
Carroll. 2011. Trafficking of B cell antigen in lymph nodes. Annu. Rev. Immunol. 
29: 215–233. 
 
51. Link, A., F. Zabel, Y. Schnetzler, A. Titz, F. Brombacher, and M. F. Bachmann. 
2012. Innate immunity mediates follicular transport of particulate but not soluble 
protein antigen. J. Immunol. 188: 3724–3733. 
 
52. Pereira, J. P., L. M. Kelly, Y. Xu, and J. G. Cyster. 2009. EBI2 mediates B cell 
segregation between the outer and centre follicle. Nature 460: 1122–1126. 
 
53. Green, J. A., and J. G. Cyster. 2012. S1PR2 links germinal center confinement and 
growth regulation. Immunol. Rev. 247: 36–51. 
 
54. Coffey, F., B. Alabyev, and T. Manser. 2009. Initial clonal expansion of germinal 
center B cells takes place at the perimeter of follicles. Immunity 30: 599–609. 
 
55. MacLennan, I. C. 1994. Germinal centers. Annu. Rev. Immunol. 12: 117–139. 
 
56. Victora, G. D., and M. C. Nussenzweig. 2012. Germinal centers. Annu. Rev. 
Immunol. 30: 429–457. 
 
57. Shlomchik, M. J., and F. Weisel. 2012. Germinal centers. Immunol. Rev. 247: 5–10. 
 
 24 
58. Haberman, A. M., and M. J. Shlomchik. 2003. Reassessing the function of immune-
complex retention by follicular dendritic cells. Nat. Rev. Immunol. 3: 757–764. 
 
59. Victora, G. D., T. A. Schwickert, D. R. Fooksman, A. O. Kamphorst, M. Meyer-
Hermann, M. L. Dustin, and M. C. Nussenzweig. 2010. Germinal center dynamics 
revealed by multiphoton microscopy with a photoactivatable fluorescent reporter. 
Cell 143: 592–605. 
 
60. Dogan, I., B. Bertocci, V. Vilmont, F. Delbos, J. Mégret, S. Storck, C.-A. Reynaud, 
and J.-C. Weill. 2009. Multiple layers of B cell memory with different effector 
functions. Nat. Immunol. 10: 1292–1299. 
 
61. Taylor, J. J., K. A. Pape, and M. K. Jenkins. 2012. A germinal center-independent 
pathway generates unswitched memory B cells early in the primary response. J. Exp. 
Med. 209: 597–606. 
 
62. Taylor, J. J., M. K. Jenkins, and K. A. Pape. 2012. Heterogeneity in the 
differentiation and function of memory B cells. Trends Immunol. 33: 590–597. 
 
63. Shlomchik, M. J., and F. Weisel. 2012. Germinal center selection and the 
development of memory B and plasma cells. Immunol. Rev. 247: 52–63. 
 
64. Allen, C. D. C., and J. G. Cyster. 2008. Follicular dendritic cell networks of primary 
follicles and germinal centers: phenotype and function. Semin. Immunol. 20: 14–25. 
 
65. Wang, X., B. Cho, K. Suzuki, Y. Xu, J. A. Green, J. An, and J. G. Cyster. 2011. 
Follicular dendritic cells help establish follicle identity and promote B cell retention 
in germinal centers. J. Exp. Med. 208: 2497–2510. 
 
66. Fu, Y. X., and D. D. Chaplin. 1999. Development and maturation of secondary 
lymphoid tissues. Annu. Rev. Immunol. 17: 399–433. 
 
67. Victoratos, P., J. Lagnel, S. Tzima, M. B. Alimzhanov, K. Rajewsky, M. Pasparakis, 
and G. Kollias. 2006. FDC-specific functions of p55TNFR and IKK2 in the 
development of FDC networks and of antibody responses. Immunity 24: 65–77. 
 
68. Nossal, G. J., A. Abbot, J. Mitchell, and Z. Lummus. 1968. Antigens in immunity. 
XV. Ultrastructural features of antigen capture in primary and secondary lymphoid 
follicles. J. Exp. Med. 127: 277–290. 
 
69. Hanna, M. G., and A. K. Szakal. 1968. Localization of 125I-labeled antigen in 
germinal centers of mouse spleen: histologic and ultrastructural autoradiographic 
studies of the secondary immune reaction. J. Immunol. 101: 949–962. 
 
70. Tew, J. G., T. E. Mandel, R. P. Phipps, and A. K. Szakal. 1984. Tissue localization 




71. Szakal, A. K., M. H. Kosco, and J. G. Tew. 1988. A novel in vivo follicular 
dendritic cell-dependent iccosome-mediated mechanism for delivery of antigen to 
antigen-processing cells. J. Immunol. 140: 341–353. 
 
72. Yoshida, K., T. K. van den Berg, and C. D. Dijkstra. 1993. Two functionally 
different follicular dendritic cells in secondary lymphoid follicles of mouse spleen, 
as revealed by CR1/2 and FcR gamma II-mediated immune-complex trapping. 
Immunology 80: 34–39. 
 
73. Shikh, El, M. E., R. El Sayed, A. K. Szakal, and J. G. Tew. 2006. Follicular 
dendritic cell (FDC)-FcgammaRIIB engagement via immune complexes induces 
the activated FDC phenotype associated with secondary follicle development. Eur. 
J. Immunol. 36: 2715–2724. 
 
74. Barrington, R. A., O. Pozdnyakova, M. R. Zafari, C. D. Benjamin, and M. C. 
Carroll. 2002. B lymphocyte memory: role of stromal cell complement and 




























GENERATION OF A NOVEL Cr2 GENE ALLELE BY  
HOMOLOGOUS RECOMBINATION THAT  
ABROGATES PRODUCTION OF Cr2  
BUT IS SUFFICIENT FOR  
EXPRESSION OF Cr1 
 
Luke R Donius, Christopher M Orlando, Janis J Weis, and John H Weis. 2013. 
Generation of a novel Cr2 gene allele by homologous recombination that abrogates 
production of Cr2 but is sufficient for expression of Cr1. Immunobiology In Press. 
 
Reproduced with permission. 
Copyright © 2013 Elsevier 
 
Abstract 
The enhancing effects of the complement system for humoral immunity have 
primarily focused upon the recognition of complement-bound foreign antigens by a co-
receptor complex of the antigen-specific B cell receptor (BCR) and complement receptor 
2 (Cr2). In vivo experiments using Cr2 gene deficient mice (which lack the expression of 
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both the Cr1 and Cr2 proteins) do demonstrate depressed humoral responses to 
immunization but cannot be used to define specific contributions of the singular Cr1 or 
Cr2 proteins on B cell functions.  To study the effect of a Cr2 deficiency in a Cr1 
sufficient environment, we created a mouse line in which the alternative splice site 
required for the expression of the Cr2 isoform was removed. This mouse line, Cr2KO, 
still expressed Cr1 on B cells but was deficient for the full length Cr2 protein. 
Surprisingly, a new alternative splice within the Cr2 gene created a truncated product that 
encoded a novel protein termed iCr2 that was expressed on the surface of the cells. The 
Cr2KO mouse thus provides a new model system for the analysis of Cr1 and Cr2 
functions in the immune response of the mouse.  
 
Introduction 
The enhancing effects of complement for humoral immunity have been apparent 
since the foundational studies of Pepys (Pepys, 1974), and the identification of the 
enhancement of B cell activation through complement receptor (CR) 2 binding of 
complement-bound antigen (Carter et al., 1988). This well-accepted model of CR2 
function relies initially on activation of the complement system by one of the three 
pathways: classical, alternative, or mannose-binding lectin. All three pathways lead to 
cleavage and deposition of complement component 3 (C3) fragments on antigen. The 
iC3b and C3d(g) fragments maintain a covalent bond with the antigen and act to direct 
the antigen to Cr2/CR2 via the iC3b/C3d(g) binding site on the proteins (Molina et al., 
1995; Pramoonjago et al., 1993). (Cr1/Cr2 versus CR1/CR2 will be used here to clearly 
differentiate the mouse from the human proteins, respectively.)  In vitro experiments 
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extensively defined the enhancement of B cell responses by CR2 (Carter et al., 1988; 
Matsumoto et al., 1993; Matsumoto et al., 1991) and the overlapping binding, co-
association, and co-activation characteristics for Cr2 (Krop et al., 1996; Molina et al., 
1994).   
Cr2 null mouse lines (Cr1/2KO) have further supported the hypotheses that Cr2 
gene products expressed by B cells and follicular dendritic cells (FDC) are critical for the 
detection of antigen and the generation of optimal antibody responses (Haas et al., 2002; 
Molina et al., 1996). The mouse Cr2 gene, unlike the human, creates both the Cr1 and 
Cr2 proteins from a single gene. The same signal sequence – encoding exon is 
alternatively spliced to either the domain encoding the first short consensus repeat (SCR) 
domain of the gene (thus generating the 190,000da Cr1 protein) or the exon encoding the 
seventh and eighth SCR (Figure 2.1a) domains of the Cr2 gene, which represent the most 
N-terminal coding sequences of the mature Cr2 protein (145,000da).  The sequence of the 
Cr2 protein is thus fully included within that of the Cr1 protein. Recently, we have found 
that this alternative splicing pattern is unique to B cells in that murine FDCs express only 
Cr1 protein from Cr2 gene transcripts (Donius et al., 2013). 
The extensive research on the Cr1/2KO mice has not fully discriminated the roles 
of the Cr1 and Cr2 proteins. The 6 N-terminal SCR domains of the Cr1 protein (which 
are not included in the Cr2 protein) can act as a co-factor in the regulation of C3 
convertase stability and function (Molina et al., 1994), and recent studies have suggested 
that Cr1 may be important in regulating complement activation in the immune 
microenvironment (Jacobson et al., 2008; Seregin et al., 2009). To define the functions of 




Figure 2.1. Schematic diagram and confirmation of Cr2 alternative splice site disruption. 
(a) The exons of the Cr2 gene are shown with numbers defining the number of the short 
consensus repeats (SCR) encoded within each. The initial exon denoted SS encodes the 
signal sequence. The Cr1 isoform is generated via the inclusion of all exons during 
splicing while the Cr2 isoform is generated by alternative splicing that excludes the 
exons encoding SCRs 1-6. The construct was generated from a cDNA version of the Cr2 
gene with the addition of a pACN neomycin selection marker. Arrows represent the 
approximate location of restriction sites used for cloning and mapping of homologous 
sequence used for recombination. Triangles represent the approximate location of BamHI 
and MscI restriction sites utilized to Southern blot for determination of proper 
homologous recombination. (b) Representative Southern blots are shown for proper 5’ 
and 3’ homologous recombination. BamHI restriction digestion of wild type (WT) 
genomic DNA exhibits a 19kb band detected by a radiolabeled probe. In the Cr2KO 
condition the fragment is reduced to 6kb. Homologous recombination of the 3’ region 
was determined by probing for a size reduction from 15kb to 13kb. (c) Western blot 
analysis of Cr2 gene products from WT and Cr2KO mice, as well as mice heterozygous 
for the Cr2KO insertion. 
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exclusively expresses Cr2 protein on the surface of B cells and lacks expression of either 
protein on the surface of FDCs.  
To define the specific functions of the Cr2 protein in the immune response of the 
mouse, we created an additional mouse line that specifically lacks the Cr2 protein but still 
produces Cr1. This mouse, dubbed Cr2KO, was created by homologous recombination 
within the Cr2 gene with a construct that removed the alternative splice junction utilized 
in B cells to create the Cr2 protein. Analysis of mice generated from this recombination 
demonstrated expression of the full length Cr1 protein on B cells but the loss of Cr1 
expression (and Cr2 gene expression) on FDCs, suggesting the disruption of an FDC-
specific transcriptional enhancer site within the Cr2 gene.  Intriguingly, the removal of 
the native alternative splice site in the Cr2KO construct resulted in the utilization of an 
internal cryptic splice site, generating a truncated Cr2 gene product, termed iCr2, that 
lacks the iC3b/C3d(g) binding sites present on the normal Cr2 protein. The Cr2KO 
animals thus represent a novel animal model with which to functionally analyze the role 
of the Cr1 protein on the surface of B cells in the absence of functional Cr2. 
 
Materials and Methods 
Generation of the Cr2KO mouse 
The pKS+ Bluescript vector was used as a backbone for the creation of the 28kb 
construct. Using primers (#4151 5’-
GTGGTCCTTATTTCTAGGTCAGTGTAAGTTGCTGC-3’ and #4152 5’-
GTTTTAATTTCCTACTTACCACTCTCACAGACTGGCAG-3’), a 1250bp cDNA 
version of the exons for SCRs1-8 of Cr1 was amplified using the long-distance high-
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fidelity DNA polymerase Platinum Pfx (Invitrogen, Carlsbad, CA). The amplicon was 
additionally modified by PCR utilizing primers with overhang sequences for the 
restriction fragments XhoI and SbfI, 5’ and 3’, respectively. This new SCRs1-8 fragment 
was cloned and ligated via XhoI and SbfI into the mouse Cr2 gene NotI-XhoI restriction 
fragment and 3’ to the SbfI-SalI restriction fragment (Figure 2.1a). The XhoI site of the 
resulting SCR1-8 construct with homology arms was utilized for insertion of the germline 
self-deleting neomycin resistance construct pACN (Bunting et al., 1999). The entire 
construct was flanked by the TK1TK2 thymidine kinase-containing negative selection 
construct. Electroporation of the Cr2KO vector into mouse strain 129-derived embryonic 
stem cells as well as blastocyst injection and implantation for the generation of chimeras 
was performed by the University of Utah Transgenic and Gene Targeting Mouse Core. 
Before blastocyst injection mouse embryonic stem cell clones were screened for 
homologous recombination by Southern blot. Restriction digestion of genomic DNA 
using BamHI produced a reduction in size from 19kb for wildtype (WT) to 6kb for 
proper homologous recombination of the 5’ homology arm of the vector (Figure 2.1b). 
The MscI digestion was used to probe for a reduction from 15kb to 13kb upon 
homologous recombination of the 3’ arm. Germline transmission of the Cr2KO allele was 
identified by tail or ear biopsies using PCR to generate a 193bp product (primers: #4934 
Fwd 5’-CTCCATGGTTCTGTGCATATAAACACGGGTATCG-3’ and #4937 Rev 5’-
CCATTGGAGATGGCTGGAGGTGACTCACAAGG-3’). The WT condition was 
delineated using PCR to identify a 329bp product (primers: #4935 Fwd 5’- 
GTAAATACAAAAGCACAGTCTCTTTGACTTGC -3’ and #4936 Rev 5’-
GATACAATACATGTAGCAGACGAGTCACCAA-3’). All Cr2KO and WT mice as 
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well as mice heterozygous between WT and Cr2KO were mixed background C57BL/6 
and 129 mice. Cr1/2KO mice were raised on site and are progeny of the Cr2-/- described 
previously (Haas et al., 2002). Experiments were performed using 8-16-week-old mice 
unless otherwise noted. All mice were housed at the Comparative Medicine Center 
(University of Utah Health Sciences Center) in accordance with the National Institutes of 
Health Guidelines on the Care and Use of Laboratory Animals.     
  
Follicular dendritic cell preparation 
To analyze follicular dendritic cell transcript and protein content, the 
hematopoietic compartment of mice was ablated via irradiation of mice with 900cGy two 
days prior to spleen isolation. The stroma of the spleen was isolated by straining the 
spleen through 100µm nylon mesh. RNA was isolated as previously described (Zabel et 
al., 1999). Briefly, the splenic stroma from irradiated mice was homogenized in 4M 
guanidine isocyathionate solution and centrifuged overnight at 30,000rpm on a 5.7M 
CsCl gradient. The pellet was resuspended in nuclease free water and isolated by ethanol 
precipitation. The precipitate was resuspended in nuclease free water and cDNA was 
generated. Protein isolation was performed as described for immunoprecipitation by 
lysing the stroma in 0.5% NP40 lysis buffer. Lysates were centrifuged for 10 minutes at 
14,000 rpm and 4°C to remove nuclei and other insoluble material.  Samples were then 





Western blot analysis 
Proteins were separated on TGX SDS-PAGE gels (Bio-Rad, Hercules, CA) and 
transferred to PVDF membrane.  Membranes were blocked in 5% milk 0.2% Tween-20 
in 1X TBS. Detection antibodies used were as follows: goat anti-Cr1/2 (Santa Cruz #m-
19, Dallas, TX), rabbit anti-actin (Sigma-Aldrich #A2066, St. Louis, MO), rabbit anti-
MEK1/2 (ERK1/2)(Cell Signaling #9122S, Danvers, MA), and rabbit anti-CD19 (Santa 
Cruz Biotechnology #sc-8500-R, Dallas, TX).  Actin, ERK1/2, and CD19 were all 
visualized with HRP-conjugated secondary donkey anti-rabbit IgG (Jackson 
Immunoresearch #711-035-152, West Grove, PA).  The goat anti-Cr1/2 was visualized 
using an HRP-conjugated bovine anti-goat IgG (Jackson Immunoresearch #805-035-180, 
West Grove, PA). 
 
Cr1/2 immunoprecipitation 
After preparation of single cell suspensions of murine splenocytes and lysis of red 
blood cells with ACK lysis buffer, live cells were counted by trypan blue and 5.5x107 
cells were collected.  Cells were resuspended in 1mL NP40 lysis buffer (0.5% NP40, 
50mM Tris-HCl (pH 7.5), 150mM NaCl, 0.5mM EDTA, and protease inhibitors 
(Complete Ultra protease inhibitor cocktail, Roche, Foster City, CA). Cells were 
incubated in lysis buffer for 30 minutes at 4°C with rotation. Lysates were then 
precleared by the addition of 60µL of a 10% suspension of protein G agarose beads 
(P7700, Sigma, St. Louis, MO) in PBS followed by 15-minute incubation at 4°C with 
rotation, centrifugation at 3,000 rpm for 10 minutes at 4°C, and transfer of the 
supernatant to a fresh 1.5ml tube.  Aliquots containing approximately 5.5x106 cell 
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equivalents were taken, 1.5µg of antibody for precipitation were added, and samples were 
incubated overnight at 4°C with rotation.  Precipitation of immunoconjugates was 
accomplished by the addition of 60µL of 10% protein-G agarose bead suspension, 
incubation for 30 minutes at 4°C with rotation, and centrifugation at 3,000 rpm for 10 
minutes.  The beads were then washed three times with buffer containing 10mM Tris-
HCL buffer (pH 7.5), 0.1mM EDTA, and 0.05% NP40.  Pellets were resuspended in 
50µL of 2x SDS-PAGE sample buffer and boiled for 5 minutes.  Samples were then 
centrifuged at 14,000 rpm for 5 minutes at 4°C, and supernatant was transferred to a fresh 
tube and stored at -80°C until western blot analysis.  
 
Immunohistochemistry of splenic cross-sections 
Sectioning and immunohistochemistry were performed as described previously 
(Donius et al., 2013). Briefly, OCT (Sakura Finetek USA, Torrance, CA) embedded 
spleens were sectioned on a cryostat at 10-12µm. Cr1 was detected using the biotinylated 
anti-Cr1 antibody clone 8C12 and Cr1/2 were detected using the biotinylated anti-Cr1/2 
antibody clone 7E9. Streptavidin conjugated horseradish peroxidase (HRP) was used to 
detect the antibodies and was visualized using 3, 3’-diaminobenzidine (DAB) (Vector 
Laboratories, Burlingame, CA).  
 
Biotinylation of cell surface proteins 
Total mouse splenocytes were collected and washed three times with PBS (pH 
8.0).  Cells were then resuspended at 2.5x107 cells/mL in 2.5mM EZ-Link Sulfo-NHS-
Biotin (Thermo Scientific, #21217, Waltham, MA) in PBS (pH 8.0) and incubated at 4° 
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C for one hour with rotation.  Unreacted biotinylation reagent was quenched and removed 
by three washes with 100mM glycine in PBS (pH 8.0).  Labeled cells were then lysed at 
5.5x107 cells/mL 0.5% NP40 lysis buffer for 30 minutes at 4°C with rotation.  For every 
1.5mL of cell lysate, 1mL of avidin-sepharose slurry (Protein Mods, #AVG, Madison, 
WI) was washed three times with 1% NP40 in PBS (pH 7.2).  After removal of the last 
wash, cell lysates were added to settled avidin sepharose gel and incubated at room 
temperature for 1 hour with rotation.  Avidin sepharose gel was transferred to a fresh 
microcentrifuge tube and washed five times with 1% NP40 in PBS (pH 7.2).  Settled 
avidin sepharose gel was resuspended in a volume of 4X SDS-PAGE sample buffer 
approximately equal to the volume of gel, boiled for 7 minutes, and placed on ice for 7 
minutes.  Samples were centrifuged at 14,000 rpm for 10 minutes at 4°C, and supernatant 
was transferred to a fresh tube and stored at -80°C until western blot analysis.  
Enrichment for cell-surface proteins was confirmed by blotting for ERK1/2.   
 
Characterization of the iCr2 splice site using 32P-labeled PCR 
Detection of small PCR amplicons was achieved by incorporation of 32P-labeled 
dCTP (Tan and Weis, 1992). Reaction mixes containing 0.01mCi of  32P-labeled dCTP, 
0.32mM dNTP, MgCl2 buffer (Biofire, Salt Lake City, UT), 0.5µg each primer, and 0.75 
units of Taq polymerase were brought to 10µl with deionized H2O and loaded into glass 
capillaries. Primer pairs were as follows: primer pair #1, Fwd #43 5’-
ATGGGATCCTTGGGTTCGCTC-3’ with Rev #4975 5’-
GTATGACTTCCATTACGAACAG-3’; primer pair #2, Fwd #43 with Rev #4974 5’- 
TATGAATCGTTGGAAGTGATGGGC -3’; and primer pair #3, #43 with Rev #45 Rev 
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#45 5’-GCTAGGTGAACAAGTGTACCT-3’ (Figure 2.2a and b). Capillary tube ends 
were sealed by melting and rapid amplification was performed using an air thermocycler 
for 16 to 25 cycles. PCR reactions were heated to >95oC in formamide containing loading 
buffer and immediately loaded onto polyacrylamide sequencing gel under denaturing 
conditions. The gel was transferred to chromatography paper, dried, and exposed to x-ray 
film overnight.  
 
Quantitative PCR 
Quantitative PCR was done as described previously (Donius et al., 2013). Briefly, 
cDNA generated from total spleen or spleen stroma from irradiated mice was amplified 
in a SYBar green (Invitrogen, Carlsbad, CA) containing reaction mix and the measured 
ΔCt was utilized to generate a transcript number relative to β-actin ΔCt. Primers used for 
Cr1, Cr1/2, and β-actin were as previously described (Debnath et al., 2007; Donius et al., 
2013; Roundy et al., 2009). 
 
Flow cytometry 
Flow cytometric analysis was performed as previously described (Donius et al., 
2013). Briefly, splenocytes were isolated by straining spleens through 100µm nylon mesh 
into ice cold FACS buffer (0.5% BSA, 2mM EDTA in PBS). Bone marrow from mice 
was isolated by flushing tibias and femurs with ice cold 0.5% BSA in PBS and straining 
through a 100um strainer and processed as below. Red blood cells were lysed with ACK 
buffer and the remaining cells were incubated in antibody mix. Antibodies used were as 
follows: eBioscience (San Diego, CA) monoclonals anti-B220-PerCP/Cy5.5 (RA3-6B2), 
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Figure 2.2. Cr2KO mice produce iCr2, an N-terminal truncated version of Cr2. (a) 
Schematic of PCR products from Cr2 gene transcripts (WT) and iCr2 transcripts 
(Cr2KO) utilizing a primer specific for the signal sequence (SS) with those from exon 
sequences encoding SCR 7/8 (primer set #1), SCR 10a (primer set #2), or SCR 11 
(primer set #3). Cr1 encoding transcripts would not be identified with these primer sets 
due to the large size of the product. (b) The primer sets #1, #2, and #3 would predict PCR 
fragments of 866bp, 487bp, and 162bp fragments, respectively, in WT samples while a 
PCR fragment of 476bp from primer set #1 and 97bp from primer set #2 would be 
predicted from Cr2KO cDNA samples. No PCR product from primer set #3 would be 
expected with the Cr2KO cDNA samples. (c) Radiographic detection of PCR amplified 
WT and Cr2KO cDNA samples using 32P-labeled dCTP resulted in bands corresponding 
to the sizes predicted in (a) and (b). Molecular weight markers are noted on the left side 
of the image. 
 38 
anti-CD19-PE/Cy7 and PE (clone 1D3), anti-Cr1-biotin (clone 8C12), anti-Cr1/2-PE/Cy7 
(clone 8D9), anti-Cr1/2-FITC (clone 7G6), anti-IgM-PE (clone eB121-15F9), and anti-
CD40-FITC (clone HM40-3). Additionally, the following BioLegend (San Diego, CA) 
antibodies were used: anti-IgD-AlexaFluor647 (clone 11-26c.2a), anti-CD23-biotin 
(cloneB3B4), CD43-PerCP/Cy5.5 clone 1B11 and purified anti-CD16/32 as Fc block. 
Secondary incubations were performed with streptavidin-APC whenever biotinylated  
antibodies were used. Final samples were resuspended in 500µl of FACS buffer and 
stained with 1.5µl 1mM DAPI for live/dead discrimination. All samples were analyzed 
on a FACSCantoII (BD Biosciences, San Jose, CA) and data were analyzed using FlowJo 
version 8.8.7 (Tree Star, Inc., Ashland, OR) 
 
Statistical analysis 
Statistical analysis and graphs were generated using Prism version 5.0c 
(GraphPad Software, Inc., San Diego, CA).  
 
Results 
Creation of a Cr2- but not Cr1-deficient mouse 
A Cr2 deficient, Cr1 sufficient, mouse in which Cr1 is expressed in a cell- and 
stage-specific manner has long been sought as a model for investigating the role of 
complement augmentation of B cell responses. The challenge in creating such a mouse 
was to leave the transcriptional control apparatus intact, but to deprive the Cr2 gene 
transcripts of the option to create the Cr2 protein-specific alternative splice.  To block the 
generation of transcripts encoding the Cr2 protein but not those encoding Cr1, we devised 
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a strategy by which the exons encoding SCR domains 1 through 8 were fused (Figure 
2.1a).  Normally, B cells process Cr2 gene transcripts to splice the domain encoding the 
signal sequence (SS) to the domain encoding SCR1 (and all of the remaining exons) to 
create the Cr1 protein. The B cell alternative splice of the Cr2 gene transcript splices the 
SS-encoding exon to that encoding the SCR7/8 (and all of the remaining exons) to create 
the Cr2 protein. We proposed that removing this alternative splice site (just upstream of 
the exon encoding SCR7/8) would block the production of the Cr2 protein and instead 
force all of the Cr2 gene transcripts to encode the Cr1 protein. A construct containing a 
cDNA fusion of the SCRs 1-8 (thus removing the alternative splice junction) was ligated 
to the testes specific self-deleting pACN neomycin resistance gene and flanked by Cr2 
homologous DNA (Figure 2.1a). To reduce the odds of nonhomologous recombination, a 
gancyclovir sensitivity gene (thymidine kinase) was also attached. Homologous 
recombination was utilized to target the construct to the Cr2 gene of mouse strain 129 
embryonic stem (ES) cells. The resulting neomycin resistant and gancyclovir insensitive 
clones were screened by Southern blot for the predicted insertion of novel BamHI and 
MscI restriction sites resulting in 19kb to 6kb and 15kb to 13kb size reductions in Cr2 
restriction digest fragments, respectively (Figure 2.1a and b). A single ES line was used 
to generate the Cr2KO mouse line. 
 To test the validity of our strategy, we obtained protein lysates from splenocytes 
of our newly generated Cr2KO mice, as well as WT and heterozygous littermates. 
Western blot analysis of these lysates revealed that Cr2 was no longer present in the 
Cr2KO samples and that Cr1 expression was maintained. Surprisingly, Cr2KO and 
heterozygous mice when compared to WT littermates expressed reduced quantities of 
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Cr1 and produced a new protein that is detected by antibody against Cr1/2 (Figure 2.1c). 
This new protein, termed incomplete Cr2 (iCr2), was found to be about 15,000da smaller 
than WT Cr2.  
 
Defining the new iCr2 protein 
 The splenic lysates from the Cr2KO animal demonstrated two proteins, one 
identical in size to Cr1 and a second (iCr2) that was smaller than the WT Cr2 protein, 
suggesting that iCr2 could be a new alternatively spliced product from the Cr2 gene 
transcripts. The decrease in size of the iCr2 product, compared to WT Cr2 protein, was 
about that predicted from the loss of two SCR domains. To identify the precise exon 
order in the Cr2 gene transcripts that could encode this iCr2 protein, we designed primers 
embedded within the exons corresponding SCR7/8, SCR10a, and SCR11 to pair with a 
primer located in the signal sequence (SS) encoding exon (Figure 2.2a). These primer 
pairs are identified here as #1, #2, and #3, respectively. Primer pair #1, #2, and #3 
produce 866bp, 487bp, and 162bp PCR products from WT Cr2 cDNA (Figure 2.2b). We 
predicted that if the new iCr2 product was excluding the 400bp exon encoding SCR7/8 
and splicing directly from the SS exon to the SCR9 exon then pair #1 would generate a 
476bp product, #2 would generate a 97bp product, and pair #3 would not generate a 
product (Figure 2.2b). In order to ensure resolution of small PCR products, we performed 
PCR with 32P-labeled nucleotides and resolved the reactions on polyacrylamide 
sequencing gels. PCR of cDNA generated from Cr2KO splenocyte-derived RNA using 
these primers revealed products 400bp smaller than those found in WT mice (Figure 
2.2c). Predictably, primer pair #3 did not produce a product in Cr2KO cDNA. Sanger 
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sequencing of a product generated from primer pair #2 further demonstrated that splicing 
exactly joins the SS exon to the exon encoding SCR9 (data not shown). These data 
indicate that the iCr2 protein consists of sequences including SCR9 and greater. 
Therefore, this protein would not possess the C3d(g) binding site encoded within the 
SCR7/8 domains (Molina et al., 1994) but would include those C-terminal sequences 
required for membrane localization and association with CD19.  
 Molina et al. previously demonstrated that C3d binds to murine Cr2 within SCR 
7/8 and also that the anti-Cr1/2 antibody 7G6 competitively binds to this site (Molina et 
al., 1994).  Another anti-Cr2 antibody, 7E9, binds both Cr1 and Cr2 but does not compete 
for C3d binding, which suggests that it recognizes an epitope found in SCR9 or greater. 
Both antibodies also bind to the Cr1 protein while a third antibody, 8C12, is specific for 
the N-terminal sequences found only in Cr1.  These three monoclonal antibodies are all 
of rat derivation. To evaluate the potential of these antibodies to recognize the iCr2 
protein, we performed immunoprecipitations with them followed by western blot using a 
pan-Cr1/2 reactive goat polyclonal antibody.  As shown (Figure 2.3a), the 7E9 antibody 
can precipitate both the iCr2 and Cr1 proteins from the Cr2KO splenic lysates (and the 
Cr1 and Cr2 proteins from the WT lysate).  Additionally, the 8C12 antibody only 
recognizes the Cr1 protein in both the WT and Cr2KO lysates, confirming that the 
Cr2KO line does continue to produce the Cr1 protein.  Alternatively, the 7G6 antibody 
(Figure 2.3b) does not precipitate the iCr2 protein but does precipitate Cr1 and WT Cr2, 
which supports the transcript/sequence data described above. These data indicate that the 
iCr2 protein does not possess the sequences encoding SCR7/8 which encode the 
iC3b/C3d(g) binding site.  
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Figure 2.3. Elucidation of structural features of the iCr2 protein by immunoprecipitation 
and biotin labeling of cell-surface proteins. (a) Western blot analysis of proteins 
precipitated from strained spleen lysates with antibodies against regions common to Cr1 
and Cr2 (7E9) and the cofactor domain unique to Cr1 (8C12). IC, isotype control 
antibody. (b) Western blot analysis of proteins precipitated from strained spleen lysates 
with antibody (7G6) against the C3d(g) binding region of Cr1 and Cr2.  This region 
remains in Cr1 produced by the Cr2KO mouse but is absent in the iCr2 protein. IC, 
isotype control antibody. (c) Western blot analysis of cell-surface proteins identified by 
biotin-labeling and precipitated with avidin-sepharose. Enrichment for cell-surface 
proteins was confirmed by immunoblotting with antibody against the cytoplasmic protein 
ERK1/2. 
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If found on the membrane, the iCr2 protein would be predicted to contain all of 
the Cr2 protein sequences C-terminal of SCR9 including those sequences that facilitate 
co-association of the Cr1/Cr2 proteins with CD19. To determine if the iCr2 protein is 
indeed found at appropriate levels on the cell surface, we preformed surface biotinylation 
analysis of WT and Cr2KO splenocytes. Enrichment of the Cr1 and iCr2 proteins from 
Cr2KO splenocytes was comparable to the identification of Cr1 and Cr2 from WT cells 
(Figure 2.3c). The intracellular protein ERK1/2 was not detected in the biotinylated 
fraction when compared to an equivalent exposure of total cell lysate. Additionally, no 
Cr1, Cr2, or iCr2 was detected in western blot analysis of the nonbiotinylated fractions 
(data not shown), suggesting that the vast majority of the Cr1, Cr2, and iCr2 proteins are 
localized on the surface of the expressing cells.  
 
Characterization of B cell protein expression in the Cr2KO animal  
 Western blot and surface biotinylation analysis described above indicates that 
splenocytes (i.e., B cells) from the Cr2KO animal express both Cr1 and iCr2 on the cell 
surface. To compare the relative levels of expression of these proteins to Cr1 and Cr2 
expression on WT splenic B cells, we isolated splenocytes from WT and Cr2KO animals 
and conducted flow cytometric analysis using antibodies specific for Cr1 (8C12) and for 
Cr1 and Cr2 (7G6, 8D9). Flow cytometric analysis of B220+ (B cells) cells demonstrated 
that the geometric mean fluorescent intensity (gMFI) of Cr1 expression in the Cr2KO 
animals (identified with the 8C12 and 7G6 antibodies) was lower than Cr1 expressed by 
WT B cells (defined by 8C12 staining) (Figure 2.4a). The specific binding site of 
antibody 8D9 on the Cr1/Cr2 proteins is not known.  However, staining of the Cr2KO B  
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Figure 2.4. Surface expression of Cr1, Cr2, CD19, CD40, and CD23 (FceR2a) on B cells 
is modulated in Cr2KO mice. (a) Representative histograms of Cr1 (antibody clone: 
8C12), Cr1/2 (7G6), Cr1/2 (8D9), CD19, CD23, and CD40 expression on B220+ cells 
from the spleens of WT (gray line), Cr2KO (black line), and Cr1/2KO mice (gray fill). 
(b) The average geometric mean fluorescent intensity (gMFI) is graphed for B220+ cells 
from WT, Cr2KO, and Cr1/2KO mice represented in (a). Significance determined by the 
t-test shown between bars by black lines and denoted by asterisks (*p<0.05, **p<0.01, 
***p<0.001, and ns=not significant). Data representative of 2 to 3 independent analyses 
and n=5-9 for all graphs.   
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cells with the 8D9 antibody could be predicted to be additive of both Cr1 and iCr2, 
increasing the gMFI to near WT levels. The 8D9 antibody demonstrated approximately 
equal staining to that of the 7G6 and 8C12 antibodies (Cr1-specific for the Cr2KO cells), 
suggesting the epitope recognized by 8D9 is also altered by the loss of SCR7/8 in the 
iCr2 protein. Additional analysis of important receptors on B cells in the Cr2KO mice 
demonstrated identical gMFI staining for CD40 and CD23 (FceR2a) compared to WT.  
The levels of CD19 expression, however, were slightly elevated compared to WT but 
intermediate to the Cr1/2KO animal as previously described (Haas et al., 2009). The 
quantified gMFI of multiple similar flow cytometric analyses are shown in Figure 2.4b.  
 
Characterization of marrow and splenic B cell populations  
in the Cr2KO animal 
 To test the effect that Cr2 specific deletion has on B cell development, we 
assessed the subsets of marrow, splenic, and peritoneal B cells. Pro-B, Pre-B, immature B, 
and mature B cells from the mature Cr2KO animal were compared with those of WT 
(Figure 2.5a). There were no demonstrable differences in B cell development between 
WT and Cr2KO mice. To determine if the expression of Cr1 by maturing B cells was 
altered in the Cr2KO mice, the cell surface expression of Cr1 was evaluated for the 
marrow B cell populations (Figure 2.5b). Similar to the WT, the Cr2KO mice primarily 
demonstrated Cr1 expression on the mature B cells within the marrow compartment with 
a lesser level of expression on the immature B cells, again similar to that seen in WT 
mice. Therefore, the stage specific expression of Cr1 was not altered from that of WT in 









Figure 2.5. Progression of marrow B cell development in the Cr2KO animal. (a) Cell 
surface staining strategy for identifying Pro-B, Pre-B, immature B, and mature B cells in 
adult WT and Cr2KO animals. Pro-B cells are identified as CD43hi and B220+ (a, top 
panel) and the CD43lo/- subset was further delineated by expression of IgM and B220. 
Pre-B cells IgMlo B220lo, immature B cells IgMhi B220lo, and mature B cells IgMhi B220hi 
are shown (a, bottom panel). No marked differences were identified between the bone 
marrow B cell subsets of Cr2KO mice compared to WT bone marrow B cell subsets. (b) 
Cr1 expression in maturing and mature marrow B cells from WT and Cr2KO animals 
was determined using the sorting gates shown in (a). Both Cr2KO and WT mice exhibit 
the same timing of expression of Cr1 at the immature B cell stage with all mature B cells 
expressing Cr1. Cr1 expression in the Cr2KO is reduced compared to WT. Data 





Peritoneal B1 populations have been shown to be altered in the Cr1/2KO animals 
but not in the Cr1KO mouse (Ahearn et al., 1996; Donius et al., 2013). We examined B1a 
and B1b populations in the Cr2KO mice and found that they were not significantly 
different than WT (data not shown). Similarly, Cr1 expression was evident on the B1 
populations of the Cr2KO mice but at levels reduced comparably to those of the other B 
cell populations in the Cr2KO animal (data not shown). Therefore, the deletion of Cr2 in 
the Cr2KO animal did not alter the numbers or type of peritoneal B1 cells.  
B cells in the spleen can be segregated by their varied expression of IgM and IgD. 
By gating on total splenic B220+ cells, the marginal zone and transitional 1 B cells are 
identified as IgDLO IgMHI cells, while follicular mature B cells are identified by the 
marker profile IgDHI IgMLO (Loder et al., 1999). A transitional 2 immature subset can 
also be identified by this strategy as IgDHI and IgMHI. Flow cytometric analysis of splenic 
B cells, identified by expression of the B cell marker B220, did not identify any 
significant effects on frequency or total number of cells from the transitional 1, 
transitional 2, marginal zone, or follicular B cell populations (Figure 2.6a and b).  
Therefore, similar to the Cr1/2KO mouse, the Cr2KO mouse has normal B2 populations 
of splenic B cells.  
 
Cr2 gene product expression on follicular dendritic cells of Cr2KO mice   
 As described above, the expression of the Cr1 protein is reduced on the surface of 
the Cr2KO B cells compared to WT B cells. Previously, we have shown that FDCs do not 
produce the Cr2 protein but instead primarily express Cr1 (Donius et al., 2013).  To 
determine if FDC expression of Cr1 was also depressed in the Cr2KO animals, we first 
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Figure 2.6. Splenic B cell populations are fully represented in Cr2KO mice. (a) 
Representative plots of B220+ B cells from total live splenocytes isolated from WT, 
Cr2KO, and Cr1/2KO mice. Gates represent follicular B cells (IgDHI IgMLO), transitional 
2 B cells (IgDHI IgMHI), and the marginal zone, B1, and transitional 1 B cell populations 
(IgDLO IgMHI). (b) The total number of cells from each population were calculated using 
gate percentages for B220+ and IgM IgD parameters and the initial number of 
splenocytes counted using trypan blue. No significant differences were seen between any 





analyzed Cr1-specific transcripts in FDCs relative to that of total spleen.  Irradiation 
treatment of mice is very effective at removing virtually all B cells from the spleen, 
leaving behind the radiation-resistant stromal cells and FDCs. As shown (Figure 2.7a),  
the level of Cr1-specific transcripts was depressed in the total spleen samples (containing 
both B cells and FDCs) as well as the irradiated samples (highly enriched for FDCs), 
indicating that FDC expression of Cr1 in the Cr2KO mouse is also reduced. Western blot 
analysis of spleen lysates from these B cell depleted mice further demonstrated that Cr1 
is not expressed by FDCs, at least not at a detectable level (Figure 2.7b). Splenic cross-
sections from WT and Cr2KO mice analyzed by immunohistochemistry using the anti-
Cr1 antibody clone 8C12 labels Cr2KO spleens but in a considerably reduced pattern 
compared to WT (Figure 2.7c).  
 
Discussion 
 The generation of a mouse specifically and singularly deficient in the Cr2 protein 
has been a sought-after tool for the study of the effects of the complement system on 
humoral immunity. A similar goal was advanced recently by the creation of a transgenic 
Cr1/2KO mouse line expressing human CR1/CD35 (Pappworth et al., 2011). However, in 
addition to the expression of human CR1 in a nonautochthonous environment, these mice  
possess other disadvantages, including premature expression of CR1 during B cell 
development, a broader cell specific expression pattern than murine Cr1, and the absence 
of the CD19 co-association exhibited by mouse Cr1. Therefore, to create a Cr2KO animal 
without these limitations, we adopted the strategy of modifying the endogenous Cr2 gene  





Figure 2.7. Follicular dendritic cell Cr2 gene expression. (a) Quantitative PCR 
measurement of Cr1 transcripts per 1000 β-actin transcripts in cDNA samples generated 
from either total splenic RNA or stromal isolations from irradiated mice (B cell depleted). 
Black lines denote statistical analysis by the t-test. (b) Western blot analysis of Cr1, Cr2, 
and iCr2 in lysates isolated from spleens using the same methods as in (a). (c) Detection 
of Cr1 utilizing antibody clone 8C12 in splenic cross-sections from naive WT and 
Cr2KO mice. All images obtained at a magnification of 4X. (**p<0.01, ***p<0.001, and 






but leave intact those coding sequences required for the Cr1 protein.  
This strategy of specifically manipulating the endogenous Cr2 gene was designed 
to leave Cr2 under the transcriptional control of its endogenous promoter in an approach 
nearly identical to that taken in the creation of the Cr1KO mouse (Donius et al., 2013). 
Creation of the Cr2KO mouse and the biological assessments of the animal described 
here, however, uncovered the importance of the intronic sequence and/or the alternative 
splice site in promoting overall expression of the Cr2 gene. 
 Both the Cr1KO and Cr2KO mice were designed to maintain the normal 
positioning of the Cr2 promoter, first exon encoding the signal sequence, and much of the 
first intron of the gene, especially the regions that are rich in transcription factor binding 
sites (Figure 2.8). While the Cr1KO mouse lacks the exons encoding the Cr1-specific 
exons encoding SCRs 1-6 (and the intervening introns), the Cr2KO animal, is primarily 
lacking only the intronic sequences between the exons encoding the first 8 SCR domains.  
There was no indication of a “new” alternative splice in the Cr1KO animal, suggesting 
that sequences that prompt the alternative splice are somewhere within the exons 
encoding the first 6 SCRs of the protein. The concept that coding exons could influence 
such a splicing event is not new.  Recent studies on alternative splicing of CD45 in T and 
B cells have identified specific residues within coding exons of that gene that are 
recognized by the HnRNP L and L-like proteins that help facilitate the complex 
alternative splicing of CD45 transcripts (Oberdoerffer et al., 2008; Preussner et al., 2012; 
Rothrock et al., 2005; Tong et al., 2005).  These target sequences that facilitate 
constitutive and inducible alternative exon splicing are comprised of CA rich sequences 




Figure 2.8. Schematic representation of the alternative splicing of the Cr2 gene seen in 
WT and Cr2KO animal lines.  The first intron sequence of 4,818bp in the WT Cr2 gene 
is present in both the Cr2KO and Cr1KO lines (denoted by shaded black box). The 
genomic span between the signal sequence (SS) exon and that encoding SCR1 is 5,392bp 
and SS to that encoding SCR7/8 is 12,972bp in the WT gene. The star in the Cr2KO and 
Cr1KO alleles denotes the insertion site of the Neo gene sequence which, during germline 
propagation, resolves to a single Lox site.  The Cr1KO allele does not demonstrate any 
alternative splice, suggesting the alternative splicing target sequence(s) is within coding 
sequences for SCRs 1-6, not the promoter or first intron of the Cr2 gene. The position of 





SCRs 4-6 of the Cr2 gene would be the likely site for such sequences and CA-rich 
HnRNP L-binding regions can be identified in silico in these coding exons (data not 
shown). Future experiments using Cr2 minigenes (similar to the minigenes constructed 
for the alternatively spliced exons of the CD45 gene) will be required to definitively 
identify sites and mechanisms controlling this alternative splicing pathway.  
 Although our goal was to create a mouse that only expressed the Cr1 protein from 
native Cr2 gene transcripts, the creation of such a mouse would have provided for much 
higher Cr1 surface expression than WT.  Instead we found the iCr2 protein was the major 
product from the targeted Cr2KO allele and the Cr1 protein was expressed below WT 
levels. The production of this iCr2 protein is nevertheless a positive outcome of the 
Cr2KO mouse since iCr2 occupies a B cell surface niche vacated in the absence of Cr2.  
The iCr2 protein lacks the sequences encoding the SCR7/8 domains which include the 
iC3b and C3d(g) binding site, but still maintains a membrane localization with full 
availability for CD19 association. The potential of iCr2 to associate with CD19 is 
especially important in light of the effects that complement receptor surface expression is 
proposed to have on CD19 expression (Haas et al., 2009). Haas et al. have shown that 
overexpression of CD19 is correlated with reduced B cell responsiveness and is 
controlled by Cr1/2 expression (Haas et al., 2005). The Cr2KO mice express an 
intermediate level of CD19 compared to WT and the Cr1/2KO mice (Figure 2.4b), 
suggesting that the Cr2KO mouse may avoid the complications associated with aberrant 
CD19 expression.  
 The most unexpected effect of deletion of the Cr2 alternative splice site is the 
reduction of Cr1 expression. This reduction is especially surprising in the FDC 
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compartment where a strong preference for Cr1 is observed (Donius et al., 2013). Instead 
of remaining the same or becoming enhanced compared to WT (which would be 
expected since the alternative splice to create the Cr2 protein is not evident in FDCs), Cr1 
was found to be reduced in FDCs at the transcriptional level and could not be detected by 
western blot (Figure 2.7a and b). The promoter and first intronic sequences of the Cr1KO, 
Cr2KO, and WT strains are virtually identical, yet the production of Cr1 in FDCs from 
the Cr2KO animal is dramatically reduced.  
 The Cr2KO animals will provide us with a unique strain with which to trace B 
cell activation within germinal centers. C3KO, Cr1KO, and Cr1/2KO animals are all 
deficient in the generation of activated germinal centers following immunization with 
sheep red blood cells (Donius et al., 2013; Wu et al., 2000). By creating bone marrow 
chimeras of Cr2KO marrow into a WT animal, we will be able to determine if B cell 
expression of the Cr2 protein is required for appropriate B cell activation in the germinal 
centers.  Similarly, by creating bone marrow chimeras of WT bone marrow into Cr2KO 
animals, we will be able to determine if the reduced level of expression of Cr1 on FDC 
seen in the Cr2KO mouse is still sufficient for appropriate germinal center B cell 
activation.  
 In total, this work describes the generation of a mouse deficient in the Cr2 
isoform of Cr2. Surprisingly, this mouse illustrates a dominant alternative splicing event 
that creates a novel iCr2 protein product that is expressed on the cell surface yet lacks the 
critical complement binding domains. The Cr2KO mice are thus functionally deficient in 
Cr2 but not Cr1; however, the effects of hypomorphism for Cr1 expression by B cells and 
FDCs are yet to be determined.  Intriguingly, the human CR2 homolog lacks a direct 
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mouse Cr1 homolog, but maintains noncoding pseudoexons with sequence conservation 
to mouse (Holguin et al., 1990). It is tempting to speculate that these pseudoexons of the 
human CR2 gene contain regulatory sequences for splicing and CR2 expression. In 
humans, CR2 produces a long and short isoform with a strong preference for the long 
isoform of CR2 on FDCs (Liu et al., 1997). Understanding the splicing control 
mechanism disrupted in the Cr2KO mouse may elucidate the mechanism behind CR2 
isoform preference in humans.   
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Figure 3.S1. Representative histograms of CD19 expression on bone marrow, peritoneal, 
and splenic B cells. A and B, Total bone marrow, peritoneal cavity, or splenic cells were 
isolated from naïve WT (filled histogram/black bars), Cr1/2KO (gray line histogram/gray 
bars), and Cr1KO (black line histogram/white bars) mice and surface CD19 expression 
was analyzed by FACS.  A, Representative histograms of CD19 expression on pro-B, pre-
B, immature, and mature B cells (top four plots); B1a and B1b cells from the peritoneal 
cavity (middle two plots); and total splenic B cells (bottom plot). B, Quantification of the 
geometric mean fluorescent intensity (gMFI) of CD19 staining by FACS analysis on B 
cell populations from the bone marrow, peritoneal cavity, and total splenic B cells. Bars 
represent the average gMFI for each genotype. CD19 gMFI was analyzed by ANOVA for 
each population and determined to be at least p<0.05 where significance is shown 
pairwise (* =p<0.05, ** = p<0.01, and ***=p<0.001 by the student’s t-test; n=3; sex 




Figure 3.S2. RT-PCR quantification of splenic inflammatory gene expression. Intron 
spanning primer sets specific for arachidonate 5-lipoxygenase (Alox5), D site albumin 
promoter binding protein (Dbp), cathepsin G (Ctsg), coagulation factor V (Fv), lipocalin 
2 (Lcn2), and killer cell lectin-like receptor, subfamily A, member 18 (Klra18) were used 
to quantify gene expression in mRNA obtained from total splenic extracts. All sample 
quantifications were normalized to 1000 β-actin transcripts. Bars represent the mean fold 
change from WT (center line) for Cr1/2KO (black) and Cr1KO (white). (WT n=3, 
Cr1KO and Cr1/2KO n=4; 12-16 week old female mice; BALB/C background; Error 




Figure 3.S3. TI-1, TI-2, and TD antigen specific immunoglobulin responses. Experiments 
were performed in which WT, Cr1/2KO, and Cr1KO mice were immunized with the 
model antigens (A) TNP-LPS (TI-1) and (B) DNP-AECM-Ficoll (TI-2), as well as (C) 
TNP-KLH (TD) at both a low dose immunization (10µg) and high dose immunization 
(100µg). All mice that were immunized with TNP-KLH were administered a secondary 
immunization at 21 days. Serum samples were collected at seven day intervals post-
immunization, and antigen specific immunoglobulin (IgM, IgG1, IgG2b, IgG2c, and 
IgG3) abundance was measured by ELISA. All data graphed here are included in the 
larger data set shown in Fig.9. (TI-1 n=4-7; TI-2 n=6; TD (low) n=4; TD (high) n=5; 8-
12 week old sex matched mice; * = p<0.05; ** = p<0.01 significance between WT and 






Figure 3.S4. FACS analysis of  C3KO GC B cells following SRBC immunization. 
Percentage of live B220+ splenocytes that are IgDint Fas+ in SRBC immunized WT and 
C3KO mice compared to mock PBS immunized mice and representative dot plots. (n=8 
immunized, n=2 PBS; Error bars represent SEM; ns=not significant; *=p<0.05, 
















MURINE COMPLEMENT RECEPTOR 1 IS REQUIRED FOR  
GERMINAL CENTER B CELL MAINTENANCE AND  
THE GENERATION OF MEMORY B CELLS BUT  




Germinal centers are the sites of maturation for high affinity immunoglobulin 
switch expressing plasma cells and memory B cells. The GC B cells that are precursors of 
these cells circulate between the light zone B cell population that interacts closely with 
antigen laden FDCs and the highly proliferative dark zone B cell population. Antigen 
retention by FDCs is dependent on Fc receptors as well as complement receptors and 
complement receptor 1 (Cr1) is the predominant complement receptor expressed by 
FDCs. The newly created Cr1KO mouse was used to test the effect of Cr1-deficiency on 
the kinetics of the germinal center reaction and the generation of IgM and switched 
memory B cell formation. Immunization of Cr1KO mice results in the normal expansion 
of B cells with a GC phenotype but these cells are not maintained at WT levels. This GC 
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B cell reduction is dependent on FDC expression of Cr1, and although it does not affect 
antigen-specific IgG titers after 37 days, memory B cell numbers are reduced.  
 
Introduction 
B cells specific for any given antigen are found in modest numbers. For large 
multi-epitope proteins mice have been shown to contain thousands of antigen-specific 
cells (1). Immunization with these antigens can produce tens of thousands of long-term 
memory B cells from this pool. Phenotypically, these cells are nearly indistinguishable 
from naïve cells by markers, but they consist of a heterogeneous population of various 
immunoglobulin classes, enhanced immunoglobulin affinity, and heightened antigen 
sensitivity. Conventionally, memory B cells have been described as emerging from the 
follicular (FO) B cell subset (B2 B cells); however, memory has also been shown to be 
generated from the B1b pool (2) and presumably from the marginal zone (MZ) B cell 
pool as well (3). Despite the considerable work being done on B cell responses and 
generation of immunological memory, the mechanistic details of these functions are still 
not fully understood. Two impediments have slowed the progress in the advance of 
memory B cell research. The first is the inherently small number of memory cells 
residing after an immune response. The second is that despite an accepted marker for 
memory B cells in humans, CD27, a similar marker has not been defined in the murine 
system. Support has been provided for the use of some markers such as CD35 (Cr1), 
CD80, and CD73 (4, 5) to delineate unswitched immunoglobulin from switched 
immunoglobulin and GC-derived from non-GC-derived but memory B cells still must be 
tracked by other means. Recently, however, B cells’ characteristic of binding the antigen 
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for which they are specific and the immunogenic nature of the fluorophore 
allophycocyanin (APC) has been utilized to track memory B cells (1, 5, 6).  
 Research has implicated the complement system and complement receptors (Cr) 1 
and 2 in the generation of memory B cell responses. Studies directly assessing the ability 
of Cr2 hypomorphic (mice in which the Cr2 gene produces low quantities of smaller 
Cr1/2 proteins (7, 8)) and Cr2-/- mice has supported a role for Cr1/2 in the generation of 
memory B cells (9-11). These effects have been attributed to the deficiency of expression 
of Cr1/2 in the stromal compartment, most notably the follicular dendritic cells (FDC). 
FDC are responsible for the trapping of antigen via Cr and Fc receptors (12, 13), and for 
orchestrating the GC reaction (14, 15). The recent development of a mouse specifically 
deficient for the Cr1 isoform of Cr2, the Cr1KO (16), and the revelation that Cr1 is the 
nearly exclusive isoform expressed by the stromal compartment FDCs (16) suggested 
that the Cr1-deficiency (Cr1KO) may result in a significant reduction in GC output of 
memory B cells. Initially, we assessed the extent of the GC B cell reduction in Cr1KO 
mice and determined that this reduction is dependent on FDC expression of Cr1. 
However, the reduction in GC B cells was not shown to be caused by a specific block in 
progression through the LZ or DZ B cell stage. It is also shown that Cr1 is required for 
memory B cell generation from the unswitched compartment, and to a lesser extent, the 
switched compartment. Intriguingly, these results were found to be independent of long-
term antibody production. I propose that these data suggest a model in which Cr1 is not 
simply a marker of derivation but a functional receptor in the determination of memory B 
cells in GC independent responses, and I propose a temporal model for plasma versus 
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memory B cell formation in which extended antigen retention is required later in GCs for 
optimal memory formation. 
 
Materials and Methods 
Mice and immunizations 
All mice used were six to twelve weeks of age. Cr1KO mice were at least N=6 
generations backcrossed on C57BL6/J and derived from those described previously (16). 
Cr1/2KO mice bred on site were Cr2-null mice on the C57BL6 background (17). C3KO 
mice bred on site were progeny of C3-null mice purchased from The Jackson Laboratory 
(Bar Harbor, ME). All WT C57BL6/J mice were purchased from The Jackson Laboratory 
or bred on site.  
 For sheep red blood cells (SRBC) (Innovative Research Inc., Novi, MI), 
immunizations SRBC were washed three times with cold PBS and resuspended in PBS 
just before use. SRBC immunizations were 2x108 SRBC delivered i.p. in 200µl. 
Immunization with APC was i.p. injection of 30µg APC (ProZyme Inc., Hayward, CA) in 
200µl of an emulsion of 1:1 complete Freund’s adjuvant. PBS controls were done 
identically with no APC. 
 
Bone marrow chimera mice 
Bone marrow chimera mice were generated as described previously (16). Briefly, 
one day prior to transplant, two doses of 550 cGy (4 hours apart) were delivered to host 
mice using an x-ray irradiator. Bone marrow was isolated into PBS from femurs and 
tibias of donor mice. WT and Cr1KO bone marrow was pooled respectively and split into 
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a ratio of one donor to three host mice. The lethally-irradiated mice were anesthetized 
with isoflurane (VetOne, Meridian, ID); the bone marrow transplant was administered 
retro-orbitally. Chimeras were administered sulfamethoxazole/trimethroprim via drinking 
water for 21 days and full reconstitution was allowed for six weeks.  
 
Flow cytometry 
Cell staining and flow cytometric analysis of dark zone, light zone, and total GC 
B cells was performed exactly as described previously (16). The following antibodies 
from BioLegend (San Diego, CA) were used: rat anti-CD83 Alexafluor647 (clone: 
Michel-19), rat anti-B220 APC/Cy7 or BV785 (RA3-6B2), rat anti-CD38 PE or PE/Cy7 
(90). The following antibodies from eBioscience (San Diego, CA) were used: rat anti-
GL7 Alexafluor488, rat anti-CXCR4 PerCP/Cy5.5 (2B11), rat anti-IgM PE (eB121-
15F9), and purified rat anti-CD16/32 (93) as Fc block. The following antibodies from BD 
Biosciences (San Jose, CA) were used: rat anti-CD95 (Fas) PE/Cy7 (Jo2), rat anti-CD4 
PE (GK1.5), and rat IgG2a, kappa PE (Catalog #553930) as an isotype control for anti-
IgM. Rat anti-IgM was proactively determined to be negative for cross-reactivity with rat 
IgM anti-GL7. Data acquisition was performed on a FACS CantoII (BD Biosciences, San 
Jose, CA) and data analysis was performed using FlowJo version 8.8.7 (Tree Star, Inc., 
Ashland, OR). 
 
APC-positive cell enrichment 
The protocol for enrichment of APC+ cells from total splenocytes was adapted 
from methods described by others (1, 5). Total splenocytes were isolated by straining 
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spleens through 100µm mesh strainers into ice cold 0.5% BSA 2mM EDTA PBS (FACS 
buffer), pelleted by centrifugation, and resuspended in ACK red blood cell lysis buffer. 
Cells were repelleted and washed with 10ml of ice cold PBS. Cells were then stained 
with 2.5µg/ml APC (ProZyme Inc., Hayward, CA) in 2% rat serum PBS with rat anti-
CD16/32 (Fc block) for 30 minutes on ice in the dark. A 12.5ml volume of FACS buffer 
was added to the cell mix and the cells were pelleted by centrifugation. APC-stained cells 
were incubated in a 500µl volume of FACS buffer with 50µl of anti-APC microbeads 
(Miltenyi Biotec Inc., Auburn, CA), covered in the dark for 15 minutes. Cells were 
washed with an additional 12.5ml of FACS buffer and pelleted by centrifugation. The 
cells were then resuspended in 500µl FACS buffer and retained on a prewashed, 
magnetized LS column (Miltenyi Biotec Inc., Auburn, CA) followed by three washes 
with 3ml of FACS buffer before removing the column from the magnet and flushing the 
retained cells free with 5ml of FACS buffer. Total cell numbers for APC-enriched and 
APC- fractions were determined by trypan blue cell counts. All APC-enriched cells (1-
3x106 viable cells) and 2-4x106 viable APC- cells were aliquotted and stained for flow 
cytometric analysis. Total APC+ cell numbers were calculated after flow cytometry by 
determining the total APC+ population of interest from enriched and negative (usually 
negligible) sorts and adding the two together. Total memory B cell numbers were 
determined by subtracting the average number of APC+ cells in PBS/CFA immunized 






Immulon 4HBX (Thermo Fisher Scientific Inc., Waltham, MA) plates were 
coated by applying 100µl of 5µg/ml APC in PBS, sealing, and incubating overnight at 
4oC. Plates were washed three times by flooding with 0.1% Tween/PBS (wash buffer) 
and discarding. Plates were blocked with 200µl volumes per well of 1% BSA/0.1% 
Tween/PBS for 1.5 hours at room temperature. Serial dilutions of serum were prepared in 
1%BSA/PBS in 96-well polystyrene plates. For IgM, dilutions were started at 1:10 and 7 
serial dilutions of 1:2 were performed to a maximum of 1:1280. IgG assessment was 
done identically with 8 dilutions from 1:100 to 1:12800. Plates were washed once. 
Diluted samples were applied to plates in 100µl volumes after blocking and incubated for 
1.5 hours at room temperature. Plates were washed three times. Horseradish peroxidase 
conjugated sheep anti-mouse IgG (#515-035-071, Jackson ImmunoResearch, West Grove, 
PA) or rabbit anti-mouse IgM (#315-035-049, Jackson ImmunoResearch, West Grove, 
PA) was diluted 1:2000 in 1% BSA/PBS and wells were incubated with 100µl volumes 
for 1.5 hours at room temperature. Plates were washed six times with wash buffer and 
horseradish peroxidase was visualized by exposure o-Phenylenediamine solution. 
Reaction was stopped with 1N HCl and absorbance was measured at 490nm with a plate 
reader (BioTek Instruments Inc., Winooski, VT). Serial diluted standards on capture 
antibody were included on each plate to assure plate to plate consistency and nonspecific 
IgM or IgG was used to assure secondary specificity. Reciprocal titers were determined 
by calculating the best fit logarithmic trendline for each sample’s serial dilution and 
calculating the reciprocal dilution necessary for a specified absorbance (OD=0.4 for IgM 
and OD=1 for IgG). 
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Statistical analysis 
Statistical analysis and graphs were generated using Prism version 5.0c 
(GraphPad Software, Inc) 
 
Results and Discussion 
Previous work from our group characterizing the Cr1KO mice revealed that the 
most striking phenotype was a reduction in the percentage of GC B cells (16). This study 
also revealed the surprising finding that the Cr1 and Cr2 isoforms are differentially 
expressed on B cells and FDCs with a preference for Cr2 on the former and near 
exclusivity of Cr1 on the latter. In light of these findings we were intrigued to investigate 
the effects and extent of the GC B cell reduction in terms of timing and the dependence 
of FDC expression of Cr1. We initially designed experiments to define the extent of the 
previously described GC B cell deficit. B cells expressing an activated, GC B cell, 
phenotype are commonly seen as early as 4 days and peak at 8 to 14 days after 
immunization with sheep red blood cells (SRBCs) (18), a trend which is seen with most 
immunizations (19). Cr1-deficiency was found to result in a reduced frequency of GC B 
cells at 7 days postimmunization (dpi) but SRBC-specific IgG titers suggested normal 
plasma cell generation. We considered the possibility that GC B cells recovered after 7 
days. To visualize the progression of the GC B cell response we immunized Cr1KO, WT, 
Cr1/2KO, and C3KO mice intraperitoneally (i.p.) with 2x108 SRBCs and harvested 
spleens at 5, 7, 9, 11, and 13 dpi (Figure 4.1a and b). Intriguingly, the expansion of B 
cells with an activated GC phenotype appeared to be initiated equally as well as WT in 
the absence of Cr1, but the maintenance of GC B cells past 7 days is markedly  
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Figure 4.1. GC B cell maintenance is Cr1 dependent but C3 and Cr2 are required for their 
generation. (a) Representative flow cytometric analysis of GC B cells, identified as the 
Fas+ GL7+ cells in the B220+ subset, from mice 5, 7, 9, 11, and 13 days post-
immunization (dpi) with 2x108 SRBCs (administered i.p.). (b) Quantification of the 
average number of splenic GC B cells for WT, Cr1KO, Cr1/2KO, and C3KO mice 
represented in (a). Data represent a compilation of two independent experiments (n=4, 
days 7, 9 and 11; n=2, days 5 and 13 and all C3KO). Significance for Cr1KO compared 
to WT as shown *p<0.05 by unpaired t-test. 
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reduced. Besides expressing the GC B cell markers GL7 and Fas, these cells are 
expressed at a time consistent with their presence in GCs. It is possible, however, that 
these cells are in fact expressing a GC B cell phenotype but are still localized in the 
perifollicular region where they expand in context with T cells before transitioning to 
GCs. From these data, it can be concluded, however, that WT-like numbers of B cells 
with a GC phenotype are present early on.  
The GC B cell time course data also demonstrate the importance of C3 ligands 
and Cr2 during B cell responses. In contrast to the normal expansion but depressed 
maintenance of GC B cells in the Cr1KO mice, the C3KO and Cr1/2KO mice exhibited 
significantly fewer GC B cells at all time points (Figure 4.1a and b). These findings are 
consistent with the hypothesis that Cr1 on FDCs retains complement bound antigen for 
GC B cell maturation, but Cr2 and C3 are necessary for B cell co-receptor enhancement 
initially. The considerable depression in Cr1/2KO GC B cells in comparison even to the 
C3KO supports the suggestion by others that these mice have additional C3 ligand 
independent deficiencies such as the subtle anergy caused by CD19 overexpression (20).  
 Cr2 expression in the Cr1KO mouse has been found to rescue many of the 
phenotypes of the Cr1/2KO mouse that are unlikely to involve an FDC component; 
normal response to TI antigens, normal naïve antibody levels, normal B1a population 
frequency, etc. Along with these data from the Cr1KO, the normal expansion of B cells 
with a GC B cell phenotype suggests that the rapid contraction of the GC B cell 
compartment is caused by the deficiency of Cr1 on FDCs. To test the effects of Cr1-
deficiency exclusively in B cells or FDCs, we took advantage of the radioresistance of 
FDCs and generated bone marrow chimeras. WT bone marrow was transplanted into 
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Cr1KO hosts (WT-->Cr1KO) and vice versa for comparison to control WT-->WT and 
Cr1KO-->Cr1KO chimeras. Immunization of these mice with 2x108 SRBCs revealed that 
GC B cells were found more frequently in WT host mice than in Cr1KO host mice at 9 
dpi regardless of the genotype of the hematopoietic compartment (Figure 4.2a and b). 
These data show that expression of Cr1 on FDC is responsible for the GC B cell 
phenotype exhibited by Cr1KO mice. Additionally, these data show that Cr1 has a 
minimal role on B cells in GCs.  
 Historically, GC reactions have been defined as containing two GC B cell subsets, 
centroblasts and centrocytes. The highly proliferative centroblasts are found in the visibly 
darker “dark zone” (DZ) and the centrocytes are found in the visibly lighter “light zone” 
(LZ) in close interaction with antigen laden FDCs (21). Recently, the Nussenzweig group 
identified markers that delineate DZ and LZ B cells from within the GC B cell niche (22). 
It may be hypothesized that in the absence of Cr1, a reduction in antigen retention would 
result in an accumulation of LZ B cells unable to cycle back at normal rates to the 
proliferative DZ B cell stage. Assessment of the percentage of GC B cells (CD38/CD4- 
Fas+) that were found in the LZ (CXCR4lo CD83hi) compartment versus the DZ 
(CXCR4hi CD83lo) compartment was not affected by Cr1 deficiency (Figure 4.3a and b). 
It should be noted, however, that as subsets of the total GC B cell population, the actual 
number of DZ and LZ B cells is reduced in the Cr1KO compared to WT mice (data not 
shown).   
 The previous Cr1KO study demonstrated that TD antigen specific IgM and IgG3 





Figure 4.2. FDC but not B cell expression of Cr1 is required for GC B cell production. 
Bone marrow chimera mice (Donor-->Host) were generated between all possible pairings 
of Cr1KO and WT mice. SRBC immunizations (2x108) were administered i.p. six weeks 
following bone marrow reconstitution of lethally irradiated hosts. (a) Analysis of the Fas+ 
GL7+ (GC B cells) from the total B220+ population of the spleen 9 days following SRBC 
immunization. (b) Cr1KO-->WT chimeras showed the same number of GC B cells per 
105 splenocytes as WT-->WT chimeras 9 dpi with SRBCs. WT-->Cr1KO and Cr1KO--
>Cr1KO chimeras showed significant reductions in GC B cells per 105 splenocytes 
compared to chimeras in which the hosts were WT. Closed circles denote chimeras in 
which FDCs are WT in contrast to open circles which represent chimeras with Cr1KO 
FDCs. Points represent individual mice with the average and standard deviation for each 
group shown. Brackets designate statistical analysis by unpaired t-test; *p<0.05. All mice 





Figure 4.3. Dark zone and light zone B cells are proportionately represented in the 
absence of Cr1. (a) Gating example showing the strategy used to identify dark zone (DZ) 
versus light zone (LZ) B cells from the GC B cell compartment. Example shown is from 
9 dpi. GC B cells were sorted from the total B220+ population of splenic B cells as Fas+ 
and CD38/CD4-. DZ B cells are characterized as CXCR4hi and CD83lo and LZ B cells are 
CXCR4lo and CD83hi. (b) Average percent of GC B cells that are DZ or LZ B cells from 
WT and Cr1KO mice 5, 7, 9, 11, and 13 dpi with 2x108 SRBCs (administered i.p.). All 
days and genotypes represent compilation of two independent experiments (n=4 for all 
days). Error bars represent SD. 
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soluble TNP-KLH (Figure 3.9a). In light of the large reduction in GC B cells in the 
Cr1KO mouse, it could be predicted that the effects on other IgG isotypes, especially 
IgG1, and on recall would be more pronounced. We considered the possibility that 21 dpi 
may still be too early to identify reductions in the GC-derived immunoglobulin. To 
investigate this possibility, we measured the total allophycocyanin (APC) specific IgM, 
as well as IgG, antibody titer from Cr1KO and WT serum samples collected 35 to 37 
days after immunization with 30µg APC emulsified in complete Freund’s adjuvant 
(CFA) (Figure 4.4). The results suggested that by 35 to 37 dpi, anti-APC IgM had 
retracted to the levels seen in mice immunized with a PBS/CFA emulsion (Figure 4.4a). 
However, there were differences between anti-APC IgM in WT and Cr1KO at this new 
baseline. This trend was seen in the PBS/CFA mice and was exacerbated significantly 
between the genotypes in the APC/CFA immunized mice. Anti-APC IgG titers, however, 
were still present at considerable levels. The anti-APC IgG titers were strikingly similar 
among the Cr1KO and WT mice (Figure 4.4b). 
 GC B cells are predominantly the precursors of high affinity and class-switched 
memory B cells. To test the effect the reduced GC B cell number in Cr1KO mice had on 
memory B cells, we used the recently described method of immunizing mice with APC 
and tracking the generation of APC+ cells. The same mice from the APC-specific 
antibody experiment were assayed 35 to 37 dpi by incubating their splenocytes with APC 
and using anti-APC magnetic beads to enrich for APC+ cells on a magnetized column. 
These cells were then analyzed by flow cytometry for their expression of the 
naïve/memory B cell phenotypic markers CD38+ GL7- and the percent of APC+ cells 




Figure 4.4. The IgG response to APC is not affected by Cr1-deficiency despite a 
significant reduction in anti-APC natural antibody of the IgM isotype. (a) ELISA analysis 
of serum from WT and Cr1KO mice 35-37 days after i.p. immunization with 30µg APC 
emulsified in CFA (APC/CFA) versus negative control PBS/CFA immunized mice.  
Reciprocal anti-APC IgM required to produce an absorbance of OD=0.4. (b) Reciprocal 
titers of anti-APC IgG from the same serum samples shown in (a). Each symbol 
represents one mouse with the mean shown by the bar. Error bars represent SEM. 




Figure 4.5. Memory B cells are reduced in the absence of Cr1. APC positive B cells from 
WT, Cr1KO, and C3KO mice were quantified 35-37 days after i.p. immunization with 
30µg APC/CFA. Prior to flow cytometric analysis, total splenocytes were incubated with 
APC and enriched by magnetic column isolation. (a) Naïve and memory B cells were 
identified using flow cytometry to sort out B220+ CD38+ GL7- subset and to assess the 
IgM and APC expression. IgM- cells were considered to be Ig switched. (b) The average 
number of naïve IgM+ and Ig switched APC+ cells is shown with error bars showing SEM. 
The number of naïve cells was calculated by determining the number of these cells 
present in PBS/CFA immunized mice. Memory B cells for APC were calculated by 
subtracting the average number of APC+ cells from PBS/CFA immunized mice from 
those found in APC/CFA immunized mice. Significantly fewer IgM+ APC+ memory cells 
were generated in Cr1KO and C3KO mice compared to WT, while slightly fewer Ig 
switched memory cells were generated. Data represents one of two experimental 
replicates. Symbols represent individual mice; *p<0.05, ns=p>0.05 by unpaired t-test.    
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percentages from the enriched and depleted fractions the number of APC+ memory B 
cells was calculated in comparison to the number APC+ naïve B cells in the PBS/CFA 
immunized mice. The number of naïve APC+ cells in the IgM+ and IgM- populations 
were not found to differ between the Cr1KO, WT, and C3KO mice (Figure 4.5b). As 
would be predicted, the APC+ IgM- naïve B cell population was very near to zero. 
Following immunization, approximately 20,000 WT APC+ IgM+ were generated and 
remained at 35-37 dpi. The Cr1KO and C3KO mice generated only about 5000-10,000 
APC+ IgM+ B cells. A similar trend was identified in the IgM- population of cells. 1500 
APC+ IgM- cells were generated in WT mice while only about 500 cells were present in 
the Cr1KO and C3KO mice. This difference was not significantly different; however, a 
second replicate not shown displayed an identical trend, albeit with reduced overall 
numbers of cells (data not shown). Further replicates will be necessary to definitively 
determine if these populations are different.        
 Together, the data in this report support an importance for Cr1 GC B cell 
maintenance and memory B cells but not antigen-specific antibody. Surprisingly, the 
memory B cell population that is most strongly affected is the IgM+ subset despite the 
minimal GC-dependence of this population. This suggests that despite the dependence of 
GC B cells on FDC expression of Cr1, an additional function of Cr1 on B cells is 
important for GC-independent responses. A function that is also suggested by the recent 
identification of Cr1 as a marker for unmutated memory B cells (4).  
If we temporarily ignore the IgM results, which may or may not be GC-derived 
and focus solely on the IgM- memory B cells and IgG antibody, a few explanations of the 
data exist. In the first model, I propose that switched plasma cells and memory B cells 
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emerge from the GC at temporally different stages. B cells with a GC B cell phenotype 
are generated readily early on after immunization and if these cells form most of the 
plasma cells, then immunoglobulin levels would be minimally affected in the Cr1KO 
mice. If the memory B cells then emerged in the later stages of the GC when Cr1KO GC 
B cells are reduced in number, then we would predict a stronger effect on the memory 
population. Additionally, the small population of GC B cells that does persist may be the 
reason for the less dramatic reduction in total IgM- memory cells. This model is not 
without precedence. In humans, where memory B cells are more readily identifiable, it 
has been suggested that plasma cells emerge between 6 and 8 days while memory B cells 
are not detected until 8 days. The caveats of this study are that it followed cells 
responding to tetanus toxin immunization in previously vaccinated people and inferred 
emergence from appearance in peripheral blood samples (23). In contrast to this study 
and the data described in this report, it has been suggested that in mice, plasma cells 
emerge later and memory B cells emerge earlier during the GC reaction (24-26). 
Takahashi et al., however, did not analyze memory B cell number or mutation content 
prior to 20 days. Inamine et al. provide the best evidence for the early emergence of 
highly mutated memory B cells; however, no comparisons were made to plasma cell 
production and memory B cells overall were normal. The most conclusive finding of 
these papers is that disruption of the GC B cell phenotype more strongly affects SHM 
than fate. It will be critical to determine the effects of Cr1-deficiency on mutation number 
and Ig affinity (SHM). Alternatively, it is possible that both IgM- memory B cells and 
IgG secreting plasma cells are equally reduced in number but by inferring relative plasma 
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cell number from antibody titers, a reduced population that is producing more antibody 
per cell has been misrepresented.   
The second explanation for the discrepancy between GC-derived antigen-specific 
IgG and IgM- memory B cell differences may come from the persistence of some GC B 
cells in the Cr1KO. It is intriguing that GC B cells although significantly reduced 
continue to persist in the Cr1KO. The current understanding of Cr in FDC antigen 
retention and exclusivity of Cr1 on FDCs strongly suggests that antigen is not properly 
retained on FDCs. If antigen on FDCs is absolutely required for GC persistence, then 
other receptors must be playing a role. Fc receptors are known to retain immune 
complexes on FDCs; however, it has been determined that this is not prevalent during the 
early portion of the primary response. At the onset of a primary response, no antigen 
specific IgG is present and Fc (gamma chain specific) receptors lag a few days in 
expression (27). There are, however, three possibilities: one that low levels of Fc 
receptors are sufficient to retain some antigen and promote limited GC B cell maturation, 
two that the use of adjuvant results in extended exposure sufficient to foster the reduced 
GC reactions observed, and three that another receptor such as the recently discovered 
Fcµ receptor may be expressed on FDCs (28). Another option is that antigen persistence 
is not necessary to maintain GCs and that Cr1 provides an unidentified function on FDCs. 
The importance of antigen persistence in long-term memory maintenance is a hotly 
debated topic (29) and at least in the early stages GC reactions have been shown to 
proceed in the near absence of persistent antigen (30). Experiments to establish the 
antigen retention abilities in the absence of Cr1 and the effects on FDCs will be needed to 
identify the specific cause of the GC reduction.  
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Concluding Remarks 
The data in this report suggest that Cr1 on FDCs is required for maintenance of 
GC B cells and for formation of memory B cells. The possibility that Cr1 has a role on B 
cells is not, however, ruled out and the strong reduction in IgM+ memory B cells suggests 
an FDC-independent contribution. Cr1 may be important in the generation of switched 
memory B cells as well, but the difference is less striking. It seems that reduced GC B 
cell numbers can at least partially fill this compartment. In light of the demonstrated Cr1-
dependent reduction in GC B cells, it is surprising that total antigen-specific IgG was not 
affected long-term. In context of the GC B cell data in which Fas+ GL7+ B cells in the 
spleen are generated at normal numbers until 7 dpi then decline relative to WT, these data 
suggest that plasma cells emerge very early on while memory B cells emerging later are 
not produced in optimal numbers. Not shown, however, is the affinity within either of 
these populations. It is possible that the WT IgG levels and inconclusiveness of the IgM- 
memory B cell data demonstrate an ability of low affinity B cells to fill these niches when 
high affinity GC B cells are not being generated. In total, the data support our previous 
identification of the importance of Cr1 on GC B cells and provide evidence that the loss 
is dependent on FDC expression of Cr1. The data do not demonstrate a straight forward 
role for Cr1, but they do provide further evidence of the requirement for FDC expressed 
Cr1 in GC B cell maintenance. The Cr1KO is an intriguing tool for the study of 
suboptimal GC conditions on humoral immune outcomes. 
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SUMMARY AND CONCLUSION 
 
A Novel Understanding of Cr1 Expression and Cr2 Splicing 
Our knowledge of the role of complement receptors in humoral immunity has 
expanded tremendously over the last three decades. This understanding was initiated 
early on by observations of the complement enhancing effects of humoral immunity and 
then pioneered by the detailing of the signaling mechanisms of CR2 by Douglas Fearon 
and colleagues (1). However, it was not determined how independent production of Cr1 
and Cr2 from the murine Cr2 gene achieved improved functionality compared to 
producing just Cr1. Cr1 contains all the binding domains found in both and would be 
predicted to function in all the roles of each. Studies suggest that using Cr1/2KO mice to 
understand the homogeneous functions of Cr1 and Cr2 may have been misleading, 
especially with respect to complement regulation by Cr1 (2-4). The predicted 
conservation of roles and sequence between Cr1/Cr2/CRRY and CR2/CR1, in mice and 
humans respectively, provide evolutionary evidence for the conservation of function 
among the three proteins (2, 5). Humans express CR2 from the Cr2 gene homolog CR2 
while they express CR1 from a separate, CR1, that is more closely related to Crry. 
However, CR1 possesses similarity with Cr1 and CRRY. CR1 is similar in size to Cr1, 
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but sequence and expression pattern evidence suggests that it is derived from duplications 
of Crry (2). We propose that these receptors accomplish three tasks. These receptors 
provide an approximately 190,000 Dalton complement receptor on their B cells and 
FDCs with a C3 convertase regulatory function (Cr1/CR1), a C3d binding receptor on 
their B cells (Cr2/CR2), and general cell surface C3 convertase regulator on all cell types 
(CRRY/CR1). The importance of the individual activities of Cr1 and Cr2, in light of 
these receptor similarities, suggests important functions of each are paralleled in humans. 
To determine how these receptors independently function in humoral immune responses, 
the Cr1KO and Cr2KO mice were generated.  
 Characterization of the Cr2KO mouse in Chapter 2 revealed the presence of a 
previously unknown splicing control mechanism present within Cr2. Introduction of the 
SCR1-8 encoding exons into the genome without introns was meant to eliminate Cr1 
expression of Cr2 and, in turn, force expression of Cr1 (Figure 2.1a). The resulting mouse 
no longer produced Cr2 but produced considerably less Cr1 and a new iCr2 protein as 
well. Immunoprecipitation of the Cr2 gene products with antibodies that are known to 
block C3d binding to Cr2 were unable to bind iCr2, suggesting that iCr2 likely does not 
bind C3 ligands (Figure 2.3a and b). The deletion of the C3d binding site along with the 
maintenance of Cr1 expression means that the Cr2KO mouse is still functionally deficient 
in only Cr1. However, the loss of Cr1 expression on FDCs and reduction in overall Cr1 
suggests that the strain’s utility will be limited to relatively specific situations, such as 
analysis of Cr2KO B cells in the context of WT FDCs.  
Analysis of Cr2 expression in these mice did, however, demonstrate the 
importance of the SCR1-8 encoding exons in controlling splicing. When the introduced 
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sequence is viewed in the context of the genomic DNA removed in the Cr1KO, it seems 
likely that a sequence within the exons encoding SCR1-8 is the only sequence present in 
WT and Cr2KO (Figure 2.8). In the case of the Cr2KO, removing the introns must 
position splicing machinery within the region of the fusion (asterisk and arc in Figure 
2.8). The machinery now splices to the next available junction and actively excises the 
SCR1-8 construct as a giant intron. The direct mechanism by which this is occurring is 
still an open question, but strongly suggests that future attempts at deletion of Cr2 from 
the Cr2 gene should take into account a better understanding of the splicing control 
involved in generating Cr2. These data also suggest that the feasibility of generating a 
Cr2KO without causing reductions in Cr2 expression may be significantly more difficult 
than predicted.  
In addition to the new understanding of Cr2 expression suggested in Chapter 2 a 
novel Cr1 expression pattern was discovered and described in Chapter 3 (Figure 3.5 and 
3.6). Despite the widely accepted use of Cr1 as an FDC-specific marker capable of 
defining FDCs in a field of B cells, Cr1 and Cr2 were assumed to be expressed evenly 
among the two cell types. I have shown here that Cr1 and Cr2 are expressed unequally on 
B cells and FDCs. B cell expression of Cr1 is not insignificant but they express Cr2 in 
excess of Cr1. FDCs on the other hand express large quantities Cr1 and hardly any Cr2 
(Figure 3.6). The implications of this expression profile are tremendous considering the 
role of complement receptors in FDC retention of antigen. This difference in expression 
provides support for our hypothesis that Cr1 and Cr2 have individual roles. The 
predominance of Cr1 on FDCs also generated the major question for the investigation of 
the role of Cr1 in GC reactions in Chapters 3 and 4. 
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Cr1-deficiency and B Cells 
Consistent with the FDC bias in Cr1 expression, the effects of Cr1-deficiency on 
B cells were found to be minor in most cases. In many cases, differences between 
Cr1/2KO and WT mice were ameliorated in the Cr1KO mouse. Among these phenotypic 
recoveries are the full WT expansion of B1a populations in the peritoneal cavity (Figure 
3.3), the full WT production of serum immunoglobulin titers in naïve mice (Figure 3.7), a 
WT response to the TI-2 antigen DNP-Ficoll (Figure 3.9a), and initial GC B cell 
expansion (Figure 4.1). The lone results suggesting that B cells are not normal in the 
absence of Cr1 were found in the analysis of the titers of natural antibody. The natural 
antibody repertoire, as assessed by three known epitopes, was determined to be 
significantly reduced in two of the three (Figure 3.8). However, in total, nearly every 
measure of B cell function revealed a WT state or response. These data are strongly 
supported by the Cr1 expression data, and caused us to generate a hypothesis that Cr1 is 
required for proper GC formation and output.   
 
Cr1-deficiency and GCs 
The importance of Cr2 gene products for the retention of antigen within follicles 
has long been known. In light of the data demonstrating the predominance of Cr1 by FDC 
and the minimal effects of Cr1 deficiency on B cell functions, we reasoned that the 
function of Cr1 is critically important for FDC function. Therefore, experiments were 
undertaken in order to investigate the role of Cr1 in TD B cell responses, which proceed 
through an FDC coordinated GC reaction. Immunizations with TD antigens demonstrated 
reductions in antigen-specific IgM and in one case, antigen-specific IgG3 (Figure 3.9). 
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These effects suggest a B cell intrinsic effect of Cr1-deficiency; however, analysis of GC 
B cell formation after SRBC immunization identified a reduction in the percentage of GC 
B cells. In order to understand the GC-independent versus GC-dependent discrepancy 
suggested by the antibody titer data and GC B cell reductions, a more detailed analysis of 
GC B cells was performed. This time course analysis of GC B cell formation revealed 
that GC B cells expanded normally during the initial phase up to about 7 days, but then 
was not maintained over the next 6 days (Figure 4.1a and b). Follow up bone marrow 
chimera experiments between WT and Cr1KO demonstrated that the GC B cell reduction 
was not affected by Cr1 deficiency on B cells but rather was completely dependent on 
FDC expression of Cr1 (Figure 4.2a and b). Together, these experiments demonstrated 
the importance of Cr1 on FDC for GC B cell biology. However, it is surprising that when 
considering the two readouts of B cell function, antibody production (Figure 3.9 and 4.4) 
and memory B cell generation (Figure 4.5), the former exhibits a strikingly WT 
phenotype across a range of immunogens. The current model does not easily describe 
these contrasting results. The time course data of GC B cells may provide the best insight 
into what may be occurring. These data suggest a model in which plasma cell versus 
memory B cell output is regulated temporally. I propose that early GC B cells are more 
frequently determined to become plasma cells while transitioning to a memory B cell 
differentiation pathway later. In terms of an infection, it is easy to imagine the benefits 
that this temporal switch would provide. Memory B cells are critical for future protection 
but if an organism does not survive, an initial infection memory is not necessary. I 
propose that it would be advantageous for the earliest GC B cells to be determined to 
make antibody producing plasma cells in order to most effectively neutralize an infection. 
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Additionally, with antigen retained by Cr1 on FDCs, the pressure to produce memory 
would not truly arise for a number of weeks when antibody titers had retracted. A 
temporal switch model is not without precedent. A study analyzing the emergence of 
plasma cells and memory B cells into the peripheral blood after immunization with the 
tetanus toxin vaccine (3-5) found that plasma cells emerged first around 6 days following 
immunization and were then followed by the appearance of memory cells at eight dpi. 
Additional studies will be necessary to fully test the temporal model of early preference 
for plasma cells, and the temporal differences in Cr1KO GC B cell reductions will 
provide an ideal tool for answering this question. 
 The significant reduction in antigen-specific IgM and IgM memory cells may be 
exacerbated by the reduction in GC B cells, but they are unlikely the result of the GC B 
cell reduction (Figure 3.9 and 4.4). Two models could explain the IgM deficiency. The 
first model is that strong, inappropriate complement activation on the B cell surface 
reduces B cell responses. The second model is that the now enhanced expression of Cr2 
(Figure 3.1) on the B cell surface provides an excess of signaling that shunts the 
responding B cells to GCs. The first of these is an attractive explanation because it 
explains why Cr1 is on B cells and supports previous findings (3, 4, 6). This model 
inherently relies on differential complement activation of the various antigens used 
(TNP-LPS, DNP-Ficoll, TNP-KLH, SRBCs, and APC); or that complement activation 
generates products that disrupt T cell responses (such as C3a). The generally stronger 
complement activation generated by proteins (6-8) is in agreement with the presence of 
antigen-specific IgM reductions associated strongly with protein antigen immunization. 
In the second model, I propose that B cells receive such a strong Cr2 signal along with 
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BCR signaling that they are quickly recruited or differentiated into fates other than IgM 
secreting plasma cells. The possibilities could include becoming a GC B cell or jumping 
to production of antigen-specific IgG, leaving the impression of a reduction in IgM. In 
fact, some of the 5 dpi with SRBC GC B cell analyses revealed that the highest 
percentage of Fas+ GL7+ cells came from Cr1KO mice and not WT (data not shown). 
However, this trend was not reflective of an overall significant excess of total GC B cells. 
Additional evidence for slightly over-activated B cells was, however, suggested in some 
other data such as the naïve antibody titers (Figure 3.7) and TI-1 antibody responses 
(Figure 3.S3a). Bone marrow chimera experiments will better identify the source of these 
deficiencies, but the evidence supports a function for Cr1, specifically in the early B cell 
response to protein (TD) antigens. Simply because the most extensive B cell response 
effects are in the IgM population does not necessarily exclude a FDC or GC-dependent 
mechanism. The extent of the FDCs’ contribution to initial antigen encounter by B cells 
is still not fully understood, and some IgM memory B cells are generated through GC-
dependent mechanisms (9). In some cases, these cells even undergo some limited affinity 
maturation (7, 8).  
 
Concluding Remarks 
 The work described here was undertaken to generate two new tools: the Cr1KO 
and Cr2KO mice. These mice were designed to specifically identify the necessary 
functions of Cr1 and Cr2, while avoiding the disadvantages of the existent Cr1/2KO 
mouse. Unforeseen changes in the expression of complement receptor products from the 
Cr2 gene in the Cr2KO suggested that poorly understood splicing mechanisms were 
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inappropriately disrupted. In contrast, the Cr1KO mouse is not only a tool to study the 
roles of Cr1, but the effects seen on GC B cells suggest that it will invaluable in the 
investigation of GCs. In these foundational studies of murine Cr1, I have demonstrated 
Cr2-independent roles for Cr1. These studies include the central findings of this 
dissertation, the defining of the FDC preference for Cr1 expression, and the extensive 
data demonstrating that while Cr1KO B cells are generally no different than WT, FDC-
dependent B cell functions were strongly affected. These data also demonstrated a role 
for Cr1 in the generation of IgM+ and IgM- memory B cells. These findings support the 
hypothesis that Cr1 is expressed on FDCs for the cultivation of GC B cell responses and 
GC output. The absence of a difference in antigen-specific IgG in response to many TD 
antigens suggests that the GC B cell reductions do not affect all GC-derived populations 
equally. These data along with GC B cell time course data suggest a temporal switch for 
fate determination of plasma cells and memory B cells. The Cr1KO will be useful in 
testing this hypothesis as well as the significant outstanding questions about the 
importance of FDC antigen retention for GC biology. Additionally, the limited but not 
absent nature of GC B cells raises questions about the extent to which a limited number 
GC B cells fill effector niches and the inhibition (or possibly enhancement) of GC B cell 
affinity maturation within these GCs.  
Finally, I propose that Cr1 on FDCs is directly analogous to CR2L on human 
FDCs. Both receptors share a near exclusivity of expression on FDCs and both are the 
larger variant of their respective Cr2 genes. These parallels suggest similar roles for the 
two in humoral immunity. Targeting of FDC expressed Cr is a strategy for enhancement 
of vaccines that has been previously suggested by members of the Cr field, specifically 
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by the Lycke group (10). The ubiquity of Cr2/CR2S expressing B cells in the vicinity of 
FDCs in both organisms suggests the targeting of vaccines specifically to Cr1/CR2L 
would produce a more specific targeting of antigen to FDCs. The use of the Cr1KO to 
elucidate the functions for which this targeting may be exploited will be invaluable.  
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